<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Microorganisms</journal-id><journal-id journal-id-type="iso-abbrev">Microorganisms</journal-id><journal-id journal-id-type="pmc-domain-id">3054</journal-id><journal-id journal-id-type="pmc-domain">microorg</journal-id><journal-id journal-id-type="publisher-id">microorganisms</journal-id><journal-title-group><journal-title>Microorganisms</journal-title></journal-title-group><issn pub-type="epub">2076-2607</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10745436</article-id><article-id pub-id-type="pmcid-ver">PMC10745436.1</article-id><article-id pub-id-type="pmcaid">10745436</article-id><article-id pub-id-type="pmcaiid">10745436</article-id><article-id pub-id-type="pmid">38138148</article-id><article-id pub-id-type="doi">10.3390/microorganisms11123004</article-id><article-id pub-id-type="publisher-id">microorganisms-11-03004</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Oral Antibiotics for Bacteremia and Infective Endocarditis: Current Evidence and Future Perspectives</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3665-2855</contrib-id><name name-style="western"><surname>Eleftheriotis</surname><given-names initials="G">Gerasimos</given-names></name><xref rid="af1-microorganisms-11-03004" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marangos</surname><given-names initials="M">Markos</given-names></name><xref rid="af1-microorganisms-11-03004" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lagadinou</surname><given-names initials="M">Maria</given-names></name><xref rid="af1-microorganisms-11-03004" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2557-4337</contrib-id><name name-style="western"><surname>Bhagani</surname><given-names initials="S">Sanjay</given-names></name><xref rid="af2-microorganisms-11-03004" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6901-3681</contrib-id><name name-style="western"><surname>Assimakopoulos</surname><given-names initials="SF">Stelios F.</given-names></name><xref rid="af1-microorganisms-11-03004" ref-type="aff">1</xref><xref rid="c1-microorganisms-11-03004" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Cobo</surname><given-names initials="F">Fernando</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-microorganisms-11-03004"><label>1</label>Division of Infectious Diseases, Department of Internal Medicine, Medical School, University of Patras, University Hospital of Patras, Rion, 26504 Patras, Greece; <email>makiseleftheriotis@yahoo.gr</email> (G.E.); <email>marangos@upatras.gr</email> (M.M.); <email>mlagad@upatras.gr</email> (M.L.)</aff><aff id="af2-microorganisms-11-03004"><label>2</label>Department of Infectious Diseases and HIV Medicine, Royal Free London NHS Foundation Trust, London NW3 2QG, UK; <email>s.bhagani@ucl.ac.uk</email></aff><author-notes><corresp id="c1-microorganisms-11-03004"><label>*</label>Correspondence: <email>sassim@upatras.gr</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2023</year></pub-date><volume>11</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">451615</issue-id><elocation-id>3004</elocation-id><history><date date-type="received"><day>01</day><month>12</month><year>2023</year></date><date date-type="rev-recd"><day>15</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>23</day><month>12</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-19 17:25:29.010"><day>19</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="microorganisms-11-03004.pdf"/><abstract><p>Bacteremia and endocarditis are two clinical syndromes that, for decades, were managed exclusively with parenteral antimicrobials, irrespective of a given patient&#8217;s clinical condition, causative pathogen, or its antibiotic susceptibility profile. This clinical approach, however, was based on low-quality data and outdated expert opinions. When a patient&#8217;s condition has improved, gastrointestinal absorption is not compromised, and an oral antibiotic regimen reaching adequate serum concentrations is available, a switch to oral antibacterials can be applied. Although available evidence has reduced the timing of the oral switch in bacteremia to three days/until clinical improvement, there are only scarce data regarding less than 10-day intravenous antibiotic therapy in endocarditis. Many standard or studied oral antimicrobial dosages are smaller than the approved doses for parenteral administration, which is a risk factor for treatment failure; in addition, the gastrointestinal barrier may affect drug bioavailability, especially when the causative pathogen has a minimum inhibitory concentration that is close to the susceptibility breakpoint. A considerable number of patients infected by such near-breakpoint strains may not be potential candidates for oral step-down therapy to non-highly bioavailable antibiotics like beta-lactams; different breakpoints should be determined for this setting. This review will focus on summarizing findings about pathogen-specific tailoring of oral step-down therapy for bacteremia and endocarditis, but will also present laboratory and clinical data about antibiotics such as beta-lactams, linezolid, and fosfomycin that should be studied more in order to elucidate their role and optimal dosage in this context.</p></abstract><kwd-group><kwd>bacteremia</kwd><kwd>endocarditis</kwd><kwd>oral treatment</kwd><kwd><italic toggle="yes">Enterobacterales</italic></kwd><kwd><italic toggle="yes">Staphylococcus</italic></kwd><kwd><italic toggle="yes">Streptococcus</italic></kwd><kwd><italic toggle="yes">Enterococcus</italic></kwd><kwd><italic toggle="yes">Pseudomonas</italic></kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-microorganisms-11-03004"><title>1. Introduction</title><p>Bacteremia and infective endocarditis are two clinical entities associated with increased morbidity and mortality. Most of the time, hospital admission is necessary, leading to increased hospital stays and healthcare costs. To date, there are no guidelines for oral step-down therapy in patients with bacteremia when the patient&#8217;s clinical condition has improved. As a result, this topic is still a matter of debate, and lots of physicians are reluctant to implement it in their everyday practice, especially among patients with <italic toggle="yes">S. aureus</italic> bacteremia or infective endocarditis [<xref rid="B1-microorganisms-11-03004" ref-type="bibr">1</xref>]. A previous survey has showed that there are geographical discrepancies regarding treatment strategies between infectious disease specialists, and lots of healthcare providers apply oral step-down only for some sources of bacteremia (more commonly acute bacterial skin/skin structure infections (ABSSSI) and urinary sources) [<xref rid="B2-microorganisms-11-03004" ref-type="bibr">2</xref>].</p><p>This strategy, except for cost minimization, could reduce healthcare-associated complications, including infections, and discomfort among patients who would otherwise receive inpatient or outpatient parenteral antimicrobial therapy (OPAT) [<xref rid="B3-microorganisms-11-03004" ref-type="bibr">3</xref>,<xref rid="B4-microorganisms-11-03004" ref-type="bibr">4</xref>]. OPAT is not adverse-event-free: 9% of 1461 OPAT courses from a study conducted in the US had at least one intravenous (IV) access complication requiring intervention [<xref rid="B5-microorganisms-11-03004" ref-type="bibr">5</xref>]. A significant event in 14.5% of the cases was reported in another study [<xref rid="B6-microorganisms-11-03004" ref-type="bibr">6</xref>]. The complication rate rises when a long-term IV antibiotic regimen is opted for. The mean time for the first complication reported in a prospective cohort for peripherally inserted central catheters (PICCs) was 16.1 days, whereas the overall complication rate was 30.2% including occlusion, accidental removal, infection, and thrombosis [<xref rid="B7-microorganisms-11-03004" ref-type="bibr">7</xref>]. Oral therapy also improves patients&#8217; quality of life by reducing in-hospital length of stay, which is one of the axes of antimicrobial stewardship, and eliminates restriction in daily activities and social life that a central catheter can cause, as well as other difficulties such as mobility restriction due to the IV catheter [<xref rid="B6-microorganisms-11-03004" ref-type="bibr">6</xref>,<xref rid="B8-microorganisms-11-03004" ref-type="bibr">8</xref>]. As a result, patients likely prefer oral antibiotic therapy [<xref rid="B9-microorganisms-11-03004" ref-type="bibr">9</xref>].</p><p>In recent years, several studies, the majority of them retrospective, have been published or are ongoing in this setting, mostly using oral antibiotic monotherapy for bacteremia and combination therapy for endocarditis, even though it is still unclear if antibiotic combination is indeed superior in some cases or if it simply serves as a safety net for patients who will have subtherapeutic blood levels of the first-choice antibiotic.</p></sec><sec sec-type="methods" id="sec2-microorganisms-11-03004"><title>2. Methods</title><p>A systematic literature search was conducted using PubMed and PubMed Central from inception until 15 October 2023. Several research terms were used to identify relevant literature: &#8220;oral&#8221; AND &#8220;bacteremia&#8221;, &#8220;oral&#8221; AND &#8220;endocarditis&#8221;, &#8220;oral penicillin&#8221; OR &#8220;oral amoxicillin&#8221; OR &#8220;oral amoxicillin/clavulanate&#8221; OR &#8220;oral cloxaxillin&#8221; OR &#8220;oral dicloxacillin&#8221; OR &#8220;oral cefalexin&#8221; OR &#8220;cefuroxime axetil&#8221; OR &#8220;cefaclor&#8221; OR &#8220;cefprozil&#8221; OR &#8220;cefixime&#8221; OR &#8220;cefditoren&#8221; OR &#8220;cefpodoxime&#8221; OR &#8220;ciprofloxacin&#8221; OR &#8220;levofloxacin&#8221; OR &#8220;moxifloxacin&#8221; OR &#8220;oral fluoroquinolones&#8221; OR &#8220;trimethoprim-sulfamethoxazole&#8221; OR &#8220;clindamycin&#8221; OR &#8220;linezolid&#8221; OR &#8220;tedizolid&#8221; OR &#8220;rifampin&#8221; OR &#8220;rifampicin&#8221; OR &#8220;metronidazole&#8221; OR &#8220;oral fosfomycin&#8221; AND &#8220;bacteremia&#8221;, &#8220;oral penicillin&#8221; OR &#8220;oral amoxicillin&#8221; OR &#8220;oral amoxicillin/clavulanate&#8221; OR &#8220;oral cloxaxillin&#8221; OR &#8220;oral dicloxacillin&#8221; OR &#8220;oral cefalexin&#8221; OR &#8220;cefuroxime axetil&#8221; OR &#8220;cefaclor&#8221; OR &#8220;cefprozil&#8221; OR &#8220;cefixime&#8221; OR &#8220;cefditoren&#8221; OR &#8220;cefpodoxime&#8221; OR &#8220;ciprofloxacin&#8221; OR &#8220;levofloxacin&#8221; OR &#8220;moxifloxacin&#8221; OR &#8220;oral fluoroquinolones&#8221; OR &#8220;trimethoprim-sulfamethoxazole&#8221; OR &#8220;clindamycin&#8221; OR &#8220;linezolid&#8221; OR &#8220;tedizolid&#8221; OR &#8220;rifampin&#8221; OR &#8220;rifampicin&#8221; OR &#8220;metronidazole&#8221; OR &#8220;oral fosfomycin&#8221; AND &#8220;endocarditis&#8221;. Results were screened for appropriateness by the first and the last author, according to title and abstract. Most relevant papers were further assessed by full content; their references were also reviewed and assessed when appropriate. Only articles published in the English language were included. Article types included clinical studies, experimental studies, clinical trials, and reviews.</p></sec><sec id="sec3-microorganisms-11-03004"><title>3. Effect of Acute Febrile Infection on Oral Antibiotic Absorption</title><p>Fever and acute infection in non-critically ill patients do not seem to affect oral absorption of antibiotics when the infection is outside the gastrointestinal tract [<xref rid="B10-microorganisms-11-03004" ref-type="bibr">10</xref>]. In addition, a retrospective study from two Brazilian intensive care units showed no difference in mortality when in-hospital step-down to oral antimicrobials was applied in initially septic patients (most often from pneumonia) that had reached clinical stability [<xref rid="B11-microorganisms-11-03004" ref-type="bibr">11</xref>]. A proportion 60.9% of the cases received fluoroquinolones, which seems rational because oral bioavailability of levofloxacin is similar to IV, even in critically ill patients [<xref rid="B11-microorganisms-11-03004" ref-type="bibr">11</xref>,<xref rid="B12-microorganisms-11-03004" ref-type="bibr">12</xref>].</p><sec id="sec3dot1-microorganisms-11-03004"><title>3.1. Bacteremia and Oral Antibiotics</title><sec id="sec3dot1dot1-microorganisms-11-03004"><title>3.1.1. Gram-Negative Bacteremia</title><sec><title><italic toggle="yes">Enterobacterales</italic> Bacteremia: Clinical Efficacy Data and Upcoming Trials</title><p>Plenty of evidence regarding oral step-down in cases of bacteremia caused by <italic toggle="yes">Enterobacterales</italic> is available from retrospective studies. All treatment outcomes have been analyzed in several publications compared with patients who received parenteral antibiotics for the whole course of infection (re-initiation of IV antibiotics, microbiological recurrence, bacteremia-related death within 21 days of negative blood cultures, 30-day urinary tract infection (UTI) recurrence, and 30-day and 90-day bacteremia recurrence and mortality); no statistically significant difference was identified in any of them [<xref rid="B13-microorganisms-11-03004" ref-type="bibr">13</xref>,<xref rid="B14-microorganisms-11-03004" ref-type="bibr">14</xref>,<xref rid="B15-microorganisms-11-03004" ref-type="bibr">15</xref>,<xref rid="B16-microorganisms-11-03004" ref-type="bibr">16</xref>,<xref rid="B17-microorganisms-11-03004" ref-type="bibr">17</xref>]. These differences remained non-significant between different sources of bacteremia (UTI, gastrointestinal tract, catheter-related bloodstream infection (CRBSI), and primary bacteremia) [<xref rid="B13-microorganisms-11-03004" ref-type="bibr">13</xref>,<xref rid="B14-microorganisms-11-03004" ref-type="bibr">14</xref>,<xref rid="B15-microorganisms-11-03004" ref-type="bibr">15</xref>,<xref rid="B16-microorganisms-11-03004" ref-type="bibr">16</xref>,<xref rid="B18-microorganisms-11-03004" ref-type="bibr">18</xref>,<xref rid="B19-microorganisms-11-03004" ref-type="bibr">19</xref>]. Oral de-escalation with fluoroquinolones has been also reported even in patients with hematological or solid malignancies without prolonged bacteremia or neutropenia for &gt;5 days [<xref rid="B20-microorganisms-11-03004" ref-type="bibr">20</xref>]. Appropriate source control upon indications (e.g., biliary drainage, removal of infected catheter, resolution of urinary obstruction) seems to be a prerequisite before oral switch [<xref rid="B14-microorganisms-11-03004" ref-type="bibr">14</xref>,<xref rid="B21-microorganisms-11-03004" ref-type="bibr">21</xref>,<xref rid="B22-microorganisms-11-03004" ref-type="bibr">22</xref>,<xref rid="B23-microorganisms-11-03004" ref-type="bibr">23</xref>]. In addition, some studies have provided us evidence about significantly higher rate of IV-line complications in those receiving IV-only antibiotics [<xref rid="B13-microorganisms-11-03004" ref-type="bibr">13</xref>,<xref rid="B20-microorganisms-11-03004" ref-type="bibr">20</xref>]. Patients who received only parenteral regimens stayed in the hospital for a median of 6&#8211;7 days, whereas the group which underwent oral de-escalation had a shorter median length of stay (4&#8211;5 days) [<xref rid="B13-microorganisms-11-03004" ref-type="bibr">13</xref>,<xref rid="B14-microorganisms-11-03004" ref-type="bibr">14</xref>,<xref rid="B15-microorganisms-11-03004" ref-type="bibr">15</xref>].</p><p>Small, randomized trials have been published in this setting, too. Park et al. revealed no difference in bacterial eradication, infection recurrence or 30-day mortality studying patients with bacteremic cholangitis after successful biliary drainage when oral ciprofloxacin was used after six days of IV treatment [<xref rid="B21-microorganisms-11-03004" ref-type="bibr">21</xref>]. Moreover, within the population of a randomized trial showing that a 1-week regimen is not inferior to a 2-week antibiotic treatment after source control in patients with Gram-negative bacteremia (mainly from UTI), 64% of short arm participants underwent oral step-down [<xref rid="B24-microorganisms-11-03004" ref-type="bibr">24</xref>]. Oral-only ciprofloxacin regimen has been also applied to an older randomized trial for hospitalized adults with pyelonephritis or other complicated UTIs where 42% and 33%, respectively, had concomitant bacteremia, with low rates of poor clinical or microbiological response [<xref rid="B25-microorganisms-11-03004" ref-type="bibr">25</xref>]. The upcoming results from the completed, randomized, non-inferiority SOAB (switch to oral antimicrobials in Gram-negative bacteremia) trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04146922">NCT04146922</ext-link>) for individuals with bloodstream infection caused by <italic toggle="yes">Enterobacterales</italic> who are afebrile and hemodynamically stable after source control and have received a minimum of 3-day IV therapy will further enhance data in this topic [<xref rid="B26-microorganisms-11-03004" ref-type="bibr">26</xref>]. Another randomized, non-inferiority trial (INVEST [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05199324">NCT05199324</ext-link>]) for non-critically ill, non-severely immunocompromised participants with Gram-negative bacteremia is at the recruiting phase and will hopefully provide evidence about outcomes and cost-effectiveness of early (within 72 h) oral switch to ciprofloxacin or trimethoprim/sulfamethoxazole (TMP/SMX) [<xref rid="B27-microorganisms-11-03004" ref-type="bibr">27</xref>].</p><p>Oral antimicrobials have been evaluated in pediatric populations against bacteremia caused by <italic toggle="yes">Salmonella</italic> spp., too. Data derived from a study in Nigeria indicate that oral ciprofloxacin for <italic toggle="yes">Salmonella</italic> bacteremia seems to be a common practice [<xref rid="B28-microorganisms-11-03004" ref-type="bibr">28</xref>]. Patients receiving ciprofloxacin may have lower rates of microbiological failure and relapse compared to cefixime [<xref rid="B29-microorganisms-11-03004" ref-type="bibr">29</xref>]. However, in a randomized trial from Pakistan, cefixime was as effective as ceftriaxone for bacteremic typhoid fever; more than 8-day treatment may not provide any additional benefit [<xref rid="B30-microorganisms-11-03004" ref-type="bibr">30</xref>,<xref rid="B31-microorganisms-11-03004" ref-type="bibr">31</xref>].</p></sec><sec><title><italic toggle="yes">Enterobacterales</italic> Bacteremia: Oral Agent Selection</title><p>Oral switch can be performed as early as three days after IV treatment initiation, once the patient is afebrile for 1&#8211;2 days and clinical and laboratory improvement has been observed [<xref rid="B13-microorganisms-11-03004" ref-type="bibr">13</xref>,<xref rid="B17-microorganisms-11-03004" ref-type="bibr">17</xref>,<xref rid="B21-microorganisms-11-03004" ref-type="bibr">21</xref>,<xref rid="B23-microorganisms-11-03004" ref-type="bibr">23</xref>]. Concerning the choice of oral agent, most studies have used high-bioavailability drugs such as levofloxacin or moderate-bioavailability drugs like ciprofloxacin and TMP/SMX [<xref rid="B13-microorganisms-11-03004" ref-type="bibr">13</xref>,<xref rid="B21-microorganisms-11-03004" ref-type="bibr">21</xref>]. When the aforementioned antibiotics were the antibiotics of choice for oral step-down in an observational study of adults with bacteremic UTI performed at 24 US hospitals, no difference in odds of recurrence between patients who received 1- or 2-week regimens was observed [<xref rid="B18-microorganisms-11-03004" ref-type="bibr">18</xref>]. In a meta-analysis, oral or IV fluoroquinolones were non-inferior to other antibiotics when used as definitive therapy even for bacteremia from extended-spectrum beta-lactamase (ESBL)-producing strains, if quinolone-susceptible; similar outcomes for fluoroquinolones or TMP/SMX versus carbapenems were observed against ESBL or AmpC producers [<xref rid="B32-microorganisms-11-03004" ref-type="bibr">32</xref>,<xref rid="B33-microorganisms-11-03004" ref-type="bibr">33</xref>]. These favorable results likely explain the higher incidence of OPAT reported in fluoroquinolone-resistant Gram-negative bacteremia [<xref rid="B34-microorganisms-11-03004" ref-type="bibr">34</xref>].</p><p>Nevertheless, in addition to their high utility, fluoroquinolones can have, like any drug, toxicity issues, too. Out of all antibiotic classes, fluoroquinolones have the highest hospitalization rates due to adverse effects according to the 2013&#8211;14 US registry which reported emergency department examinations for a drug-induced etiology [<xref rid="B35-microorganisms-11-03004" ref-type="bibr">35</xref>]. Of the cases, 14.5% that had an emergency visit in this study due to fluoroquinolone use needed hospital admission; the main adverse events consisted of allergic reactions, gastrointestinal symptoms (abdominal pain, diarrhea, bloating, vomiting), neuropsychiatric manifestations (seizures, lethargy, confusion, dizziness), musculoskeletal complaints such as tendinitis, and secondary infections, primarily <italic toggle="yes">Cl. difficile</italic> colitis and mucosal candidiasis [<xref rid="B35-microorganisms-11-03004" ref-type="bibr">35</xref>]. Fluoroquinolones should therefore be administered with great caution and close follow-up to individuals with a history of seizures, psychiatric disease, dementia, as well as QTc prolongation.</p><p>There is also evidence, however, that if beta-lactams are appropriately dosed are equally effective, provided that are able to achieve adequate serum levels. When beta-lactam antibiotics compared with fluoroquinolones or TMP/SMX in an observational study among 4089 adults with UTI plus bacteremia, non-significant differences in UTI recurrence, 30- and 90-day bacteremia recurrence and all-cause mortality were found when individuals had previously received 4&#8211;5 days of effective IV antimicrobial therapy; treatment failure was comparable for patients who received beta-lactams and fluoroquinolones in other retrospective analyses from the US and Canada, too [<xref rid="B19-microorganisms-11-03004" ref-type="bibr">19</xref>,<xref rid="B36-microorganisms-11-03004" ref-type="bibr">36</xref>,<xref rid="B37-microorganisms-11-03004" ref-type="bibr">37</xref>]. Similar results were reported by Mercuro et al., who also included several patients with intra-abdominal source of bacteremia [<xref rid="B23-microorganisms-11-03004" ref-type="bibr">23</xref>]. In addition, patients in oral beta-lactam arm experienced significantly fewer adverse events [<xref rid="B23-microorganisms-11-03004" ref-type="bibr">23</xref>]. The aforementioned study showed that a more than 10-day treatment did not have more clinical or microbiological success or less 30-day readmission rates, even for oral beta-lactams [<xref rid="B23-microorganisms-11-03004" ref-type="bibr">23</xref>]. On the other hand, beta-lactam step-down therapy was inferior to fluoroquinolones or TMP/SMX in other retrospective studies for <italic toggle="yes">Enterobacterales</italic> bacteremia [<xref rid="B22-microorganisms-11-03004" ref-type="bibr">22</xref>,<xref rid="B38-microorganisms-11-03004" ref-type="bibr">38</xref>,<xref rid="B39-microorganisms-11-03004" ref-type="bibr">39</xref>]. Oral beta-lactam administration was associated with increased risk of 90-day mortality and recurrence, mainly due to cefdinir use in some patients, which is an antibiotic not reaching adequate serum concentrations, in one study and due to low oral beta-lactam dosages in others [<xref rid="B22-microorganisms-11-03004" ref-type="bibr">22</xref>,<xref rid="B38-microorganisms-11-03004" ref-type="bibr">38</xref>,<xref rid="B39-microorganisms-11-03004" ref-type="bibr">39</xref>,<xref rid="B40-microorganisms-11-03004" ref-type="bibr">40</xref>].</p></sec><sec><title>Oral Cephalosporins for <italic toggle="yes">Enterobacterales</italic> Bacteremia: PK/PD Data</title><p>Current susceptibility breakpoints defined by European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) for oral cephalosporins cannot be implemented in bacteremia cases; for EUCAST, in particular, these breakpoints can be applied only for uncomplicated UTI. Pharmacokinetic/pharmacodynamic (PK/PD) studies showed with Monte Carlo simulations, considering the bactericidal target %<italic toggle="yes">f</italic>T &gt; minimum inhibitory concentration (MIC) &gt; 60&#8211;70%, that probability of target attainment (PTA) &gt; 90% in serum could not be achieved with regular cefuroxime dosing (500 mg bid); the same results were reported with cefditoren and confirmed in another study, even when the target was %<italic toggle="yes">f</italic>T &gt; MIC &gt; 40% [<xref rid="B40-microorganisms-11-03004" ref-type="bibr">40</xref>,<xref rid="B41-microorganisms-11-03004" ref-type="bibr">41</xref>,<xref rid="B42-microorganisms-11-03004" ref-type="bibr">42</xref>]. Considering these studies, cefaclor and cefprozil should not be choices for oral treatment of bacteremia, too [<xref rid="B40-microorganisms-11-03004" ref-type="bibr">40</xref>,<xref rid="B42-microorganisms-11-03004" ref-type="bibr">42</xref>]. Even when high-dose cefuroxime (500 mg tid) was simulated, PTA was &gt;90% only for MIC &#8804; 0.5 mg/L, thus far below the breakpoint [<xref rid="B41-microorganisms-11-03004" ref-type="bibr">41</xref>]. On the other hand, cefixime reached PK/PD target for MIC &#8804; 0.5 mg/L, but only when prescribed in high doses (400 mg bid); similar pharmacological targets seem to be achievable using cefpodoxime in the same dose [<xref rid="B40-microorganisms-11-03004" ref-type="bibr">40</xref>,<xref rid="B41-microorganisms-11-03004" ref-type="bibr">41</xref>]. Regarding cefalexin, high doses of 1 g qid and 500 mg qid can reach PTA &gt; 90% for MIC &#8804; 4 and &#8804;2 mg/L, respectively, if the target is %<italic toggle="yes">f</italic>T &gt; MIC &gt; 40%; similar findings have been also previously published [<xref rid="B40-microorganisms-11-03004" ref-type="bibr">40</xref>,<xref rid="B42-microorganisms-11-03004" ref-type="bibr">42</xref>]. Other study has reported PTA &gt; 90% (with a target of %<italic toggle="yes">f</italic>T &gt; MIC &gt; 70%) if MIC is &#8804;1.5 and &#8804;3 mg/L for 1 g tid and 1 g qid regimens, respectively (see also <xref rid="microorganisms-11-03004-t001" ref-type="table">Table 1</xref>) [<xref rid="B43-microorganisms-11-03004" ref-type="bibr">43</xref>].</p></sec><sec><title><italic toggle="yes">Pseudomonas</italic> Bacteremia: Clinical Efficacy Data</title><p>Ciprofloxacin and levofloxacin are to date the only studied and commercially available oral options against systemic infections caused by <italic toggle="yes">Pseudomonas</italic> spp. A retrospective study with <italic toggle="yes">Pseudomonas</italic> bacteremia cases revealed that 28-day mortality rate stratified by APACHE II and Pitt bacteremia score was not statistically different between patients who were treated with fluoroquinolone or antipseudomonal beta-lactam [<xref rid="B50-microorganisms-11-03004" ref-type="bibr">50</xref>]. Notably, 44.4% of patients at the fluoroquinolone group continued the drug orally after a median of six days IV [<xref rid="B50-microorganisms-11-03004" ref-type="bibr">50</xref>]. In addition, retrospective data for <italic toggle="yes">Pseudomonas</italic> bacteremia derived from a systematic review and meta-analysis did not show any worse outcomes in subjects who received fluoroquinolones, even though oral switch was applied in a substantial percentage of cases [<xref rid="B51-microorganisms-11-03004" ref-type="bibr">51</xref>].</p></sec><sec><title>Oral Ciprofloxacin for Gram-Negative Bacteremia&#8212;PK/PD and TDM Data</title><p>Oral ciprofloxacin may have less bioavailability compared to newer fluoroquinolones but is still a drug of choice from this category against Gram-negative bacteria, especially in endemic tuberculosis areas where levofloxacin and moxifloxacin are reserved for these patients. Retrospective studies have shown its potency and safety against Gram-negative bacteremia regardless of the causative microorganism [<xref rid="B52-microorganisms-11-03004" ref-type="bibr">52</xref>,<xref rid="B53-microorganisms-11-03004" ref-type="bibr">53</xref>]. When ciprofloxacin is used for bacteremia, the efficacy target should be area under the curve (AUC)<sub>0&#8211;24</sub>/MIC &#8805; 125, because probability for clinical and microbiological cure rises substantially above this limit [<xref rid="B54-microorganisms-11-03004" ref-type="bibr">54</xref>,<xref rid="B55-microorganisms-11-03004" ref-type="bibr">55</xref>]. PK/PD studies suggest high PTA for 500 mg bid orally if MIC &#8804; 0.125 mg/L; 750 mg bid is expected to be adequate for MIC &#8804; 0.25 mg/L, as is the dose of 1200 mg/day IV [<xref rid="B10-microorganisms-11-03004" ref-type="bibr">10</xref>]. These findings are corroborated by therapeutic drug monitoring (TDM) data. When 500 mg bid regimen was prescribed against strains with an MIC of 0.25 mg/L, PTA was only 41%, which rose to 72% after 1&#8211;2 days of treatment [<xref rid="B56-microorganisms-11-03004" ref-type="bibr">56</xref>]. For the EUCAST breakpoint of 0.5 mg/L for <italic toggle="yes">Enterobacterales</italic> (except <italic toggle="yes">Salmonella</italic>) and <italic toggle="yes">Pseudomonas</italic>, none of these regimens can reach PK/PD targets [<xref rid="B10-microorganisms-11-03004" ref-type="bibr">10</xref>,<xref rid="B56-microorganisms-11-03004" ref-type="bibr">56</xref>]. Only very high dosages (1 g bid) that are not suggested by European Medicines Agency could be sufficient [<xref rid="B56-microorganisms-11-03004" ref-type="bibr">56</xref>,<xref rid="B57-microorganisms-11-03004" ref-type="bibr">57</xref>]. Guideline-indicated dose reduction in patients with impaired renal function is expected to further reduce PTA because reduced renal clearance of ciprofloxacin in this context is compensated, to a great extent, by fecal elimination (see also <xref rid="microorganisms-11-03004-t002" ref-type="table">Table 2</xref>) [<xref rid="B56-microorganisms-11-03004" ref-type="bibr">56</xref>,<xref rid="B58-microorganisms-11-03004" ref-type="bibr">58</xref>]. </p></sec></sec><sec id="sec3dot1dot2-microorganisms-11-03004"><title>3.1.2. Gram-Positive Bacteremia</title><sec><title><italic toggle="yes">S. aureus</italic> Bacteremia: Clinical Efficacy Data</title><p>Oral treatment for staphylococcal bacteremia is not a novel concept. Carney et al. reported a series of 18 oncology patients with staphylococcal bacteremia who were switched to oral dicloxacillin or cefalexin 1 g qid after a mean of 9-day IV therapy from as early as the 1980s, resulting in clinical and bacteriological cure in all cases except 1 [<xref rid="B59-microorganisms-11-03004" ref-type="bibr">59</xref>]. Several retrospective studies have been published data about safety and efficacy of oral step-down in patients with bacteremia from <italic toggle="yes">S. aureus</italic>. Diego-Yag&#252;e et al. found no difference in 90-day microbiological failure, relapse, and mortality when patients with uncomplicated bacteremia who had already received IV treatment for a median of one week underwent oral de-escalation compared with a cohort that received IV-only therapy; approximately one-third of the subjects received oral fluoroquinolones and another half of them oral beta-lactams [<xref rid="B60-microorganisms-11-03004" ref-type="bibr">60</xref>]. Oral beta-lactams (mainly flucloxacillin 1 g tid) were also predominantly prescribed to 81 low-risk, mostly CRBSI, bloodstream infections in a retrospective study from New Zealand, when 5 days of IV treatment had preceded [<xref rid="B61-microorganisms-11-03004" ref-type="bibr">61</xref>]. This approach resulted in low 90-day recurrence and mortality (4% and 2%, respectively) [<xref rid="B61-microorganisms-11-03004" ref-type="bibr">61</xref>]. Another single-center study including 70 persons with variable sources of bacteremia (mainly ABSSSI) who underwent oral de-escalation reported a 7.1% 90-day clinical failure rate; 90-day readmission rate, however, was 32.9% [<xref rid="B62-microorganisms-11-03004" ref-type="bibr">62</xref>]. The most commonly prescribed oral antibiotics were linezolid, TMP/SMX and clindamycin after a median of eight days [<xref rid="B62-microorganisms-11-03004" ref-type="bibr">62</xref>]. </p><p>Similar results are available even for complicated bacteremia. P&#233;rez-Rodr&#237;guez et al. reported no differences in clinical cure, death or 90-day recurrence in an observational study that almost half of the patients had a bone infection as the source of their bacteremia, whereas hospital stay was statistically shorter in the oral step-down group (36 vs. 18 days) [<xref rid="B63-microorganisms-11-03004" ref-type="bibr">63</xref>]. Oral monotherapy was administered; two-thirds of the subjects received TMP/SMX [<xref rid="B63-microorganisms-11-03004" ref-type="bibr">63</xref>]. Unlike other sources of bacteremia, de-escalation to oral antimicrobials should not be applied before the first week of treatment in patients with bone and joint-originated infection based on the design of OVIVA trial [<xref rid="B64-microorganisms-11-03004" ref-type="bibr">64</xref>]. In addition, a retrospective cohort analysis including <italic toggle="yes">S. aureus</italic> infective endocarditis or bacteremia with epidural abscess, vertebral osteomyelitis or septic arthritis in people who inject drugs showed that microbiological failure did not differ between patients who were discharged with oral antibiotics (either monotherapy or antibiotic combination) after a 10-day IV regimen and patients who received only parenteral antibiotics [<xref rid="B65-microorganisms-11-03004" ref-type="bibr">65</xref>]. </p><p>Regarding non-observational data, a meta-analysis of older randomized trials for linezolid in <italic toggle="yes">S. aureus</italic> ABSSSI and pneumonia revealed that patients with concomitant bacteremia had received oral linezolid after 8.6 days of IV treatment [<xref rid="B66-microorganisms-11-03004" ref-type="bibr">66</xref>]. In addition, a fluoroquinolone (fleroxacin in particular)&#8211;rifampicin combination has been used orally for the whole course of treatment in <italic toggle="yes">S. aureus</italic> bacteremia versus parenteral flucloxacillin or vancomycin in a randomized trial that showed no significant difference in cure rate [<xref rid="B67-microorganisms-11-03004" ref-type="bibr">67</xref>]. However, patients from the IV arm had an 11-day longer median hospital stay [<xref rid="B67-microorganisms-11-03004" ref-type="bibr">67</xref>]. TMP/SMX, even in a dose of 320 mg/1600 mg bid, should not be used as monotherapy during the initial, IV part of treatment for bacteremia patients because it failed to meet non-inferiority criteria versus vancomycin, thus increasing treatment failure risk [<xref rid="B68-microorganisms-11-03004" ref-type="bibr">68</xref>,<xref rid="B69-microorganisms-11-03004" ref-type="bibr">69</xref>]. However, it can be used as oral step-down therapy according to all the aforementioned retrospective data, UK guidelines, as well as the results of the long awaited SABATO trial, where oral TMP/SMX 160/800 mg bid was used in 58.3% of the cases; another 32.4% of the participants received oral clindamycin 600 mg tid [<xref rid="B68-microorganisms-11-03004" ref-type="bibr">68</xref>,<xref rid="B70-microorganisms-11-03004" ref-type="bibr">70</xref>]. In this study, patients with low-risk <italic toggle="yes">S. aureus</italic> bacteremia were randomized to either an oral antimicrobial or to continue with IV therapy after 5&#8211;7 days of parenteral antimicrobial treatment; non-inferiority criteria for the composite primary endpoint (90-day relapse, evolution of deep-seated infection or mortality attributable to primary infection) were met [<xref rid="B70-microorganisms-11-03004" ref-type="bibr">70</xref>]. These data enriched the available evidence about oral treatment in bacteremia for clinically improved patients without prolonged bacteremia, concomitant pneumonia or other deep-seated infectious focus; subjects in the oral switch group hospitalized for 3.1 days less, too [<xref rid="B70-microorganisms-11-03004" ref-type="bibr">70</xref>].</p></sec><sec><title><italic toggle="yes">S. aureus</italic> Bacteremia: Duration of Treatment</title><p>Less than 2-week regimens should generally be avoided given the findings of Chong et al., where no relapses of uncomplicated <italic toggle="yes">S. aureus</italic> bacteremia occurred in patients who were treated for &#8805;14 days [<xref rid="B71-microorganisms-11-03004" ref-type="bibr">71</xref>]. Duplex ultrasonography may be helpful in order to distinguish cases of septic thrombophlebitis in apparently uncomplicated cases of staphylococcal CRBSI that could lead to the appropriate extension of treatment duration and consequently less relapse rates [<xref rid="B72-microorganisms-11-03004" ref-type="bibr">72</xref>].</p></sec><sec><title>Linezolid for <italic toggle="yes">S. aureus</italic> Bacteremia</title><p>Linezolid is suggested as the first-choice alternative drug for methicillin-resistant <italic toggle="yes">S. aureus</italic> (&#924;RSA) bacteremia by the UK guidelines when vancomycin is contraindicated [<xref rid="B68-microorganisms-11-03004" ref-type="bibr">68</xref>]. This recommendation may be easily extrapolated to oral linezolid, given the fact that this drug has excellent oral bioavailability. It should be noted here that an older randomized trial has showed that linezolid was non-inferior to vancomycin or oxacillin in patients with Gram-positive, mostly staphylococcal, CRBSI in terms of clinical or microbiological failure and mortality [<xref rid="B73-microorganisms-11-03004" ref-type="bibr">73</xref>]. Good results (17.1% 90-day infection-related readmission, 4% 90-day mortality) have been also published from 54 patients who received oral linezolid after a median of 5-day IV treatment; these subjects experienced significantly less line-associated and total adverse events requiring readmission compared with vancomycin or daptomycin OPAT [<xref rid="B74-microorganisms-11-03004" ref-type="bibr">74</xref>]. Another study for oral linezolid in this setting was a prospective cohort study from Spain with mostly uncomplicated catheter and ABSSSI-originated bacteremia [<xref rid="B75-microorganisms-11-03004" ref-type="bibr">75</xref>]. Oral switch after a median of one week resulted in 30-day mortality and 90-day relapse rates comparable to conventional parenteral regimens; patients from the IV-only group, however, had a longer hospital stay (19 vs. 8 days) [<xref rid="B75-microorganisms-11-03004" ref-type="bibr">75</xref>].</p></sec><sec><title>Clindamycin for <italic toggle="yes">S. aureus</italic> Bacteremia</title><p>Clindamycin, on the other hand, had been prescribed as oral monotherapy, mostly when ABSSSI was the source of bacteremia, after a median of six days of IV antimicrobials in a retrospective study from Australia [<xref rid="B76-microorganisms-11-03004" ref-type="bibr">76</xref>]. It is notable that, when the source of bacteremia is osteomyelitis, a classic oral dosage of 600 mg tid is probably suboptimal in patients weighing &gt;75 kg according to a PK/PD study using data from clindamycin TDM in 50 patients with bone infection; 900 mg tid is needed in such cases (see also <xref rid="microorganisms-11-03004-t002" ref-type="table">Table 2</xref>) [<xref rid="B77-microorganisms-11-03004" ref-type="bibr">77</xref>]. The reasons for this are the augmented clindamycin clearance when body weight increases, despite an oral bioavailability of 87.6%, and clindamycin bone penetration rate of approximately 30% [<xref rid="B77-microorganisms-11-03004" ref-type="bibr">77</xref>,<xref rid="B78-microorganisms-11-03004" ref-type="bibr">78</xref>]. Oral clindamycin should not be co-administered with rifampicin unless clindamycin TDM is available because in a study for osteoarticular infections, clindamycin serum concentrations (trough and peak) were systematically below the recommended therapeutic targets when combined with rifampicin [<xref rid="B79-microorganisms-11-03004" ref-type="bibr">79</xref>,<xref rid="B80-microorganisms-11-03004" ref-type="bibr">80</xref>]. In contrast, this was not the case neither for IV clindamycin in continuous infusion when co-administered with rifampicin nor for clindamycin&#8211;levofloxacin combination [<xref rid="B79-microorganisms-11-03004" ref-type="bibr">79</xref>,<xref rid="B80-microorganisms-11-03004" ref-type="bibr">80</xref>]. In particular, data from an observational PK study comparing the effect of rifampicin on IV and oral clindamycin metabolism revealed that route of administration plays a major role; when oral clindamycin was given, AUC<sub>0&#8211;8h</sub> decreased 12 times (3.1 versus 37.7 mg&#183;h/L) compared with the same continuous IV dose [<xref rid="B80-microorganisms-11-03004" ref-type="bibr">80</xref>]. Because rifampicin has only a small influence on clindamycin half-life, this effect is probably due to increased hepatic first-pass metabolism of clindamycin in the case of oral intake, thus reducing clindamycin oral bioavailability from 59.7% to 15.1% in this study [<xref rid="B80-microorganisms-11-03004" ref-type="bibr">80</xref>].</p></sec><sec><title>Fluoroquinolones for <italic toggle="yes">S. aureus</italic> Bacteremia</title><p>Fluoroquinolone monotherapy against <italic toggle="yes">S. aureus</italic> is generally not preferred in most guidelines due to on-treatment resistance issues irrespective of infection type. However, not all antibiotics of this class are the same. Moxifloxacin seems to be the most potent &#8220;anti-staphylococcal fluoroquinolone&#8221;. An older PD model has showed that the equivalent daily dose of 400 mg of moxifloxacin against <italic toggle="yes">S. aureus</italic> is 5000 mg of levofloxacin, well above the studied human daily doses, whereas in another model ciprofloxacin was probably suboptimal even in a dosage of 750 mg bid [<xref rid="B81-microorganisms-11-03004" ref-type="bibr">81</xref>,<xref rid="B82-microorganisms-11-03004" ref-type="bibr">82</xref>]. The MIC breakpoint for killing and resistance suppression for moxifloxacin 400 mg qd should be &#8804;0.06 mg/L based on a pharmacometric PK/PD model derived from plasma and target site TDM, far below the established breakpoint of 0.25 mg/L; microbial subpopulations with acquired resistance to moxifloxacin could emerge if used as monotherapy above this threshold [<xref rid="B83-microorganisms-11-03004" ref-type="bibr">83</xref>]. High-dose moxifloxacin (800 mg/day) can increase this breakpoint to &#8804;0.125 mg/L, which is a dose that has been successfully used for tuberculosis; further data are needed before applying such strategy in everyday routine (see also <xref rid="microorganisms-11-03004-t002" ref-type="table">Table 2</xref>) [<xref rid="B83-microorganisms-11-03004" ref-type="bibr">83</xref>,<xref rid="B84-microorganisms-11-03004" ref-type="bibr">84</xref>].</p><p>Moxifloxacin has also been effectively used in other biofilm-associated infections caused by <italic toggle="yes">S. aureus</italic> like orthopedic implant-related infections, either as monotherapy or in combination with rifampicin, even though studies on tuberculosis have shown that rifampicin lowers moxifloxacin serum levels by approximately 30% [<xref rid="B85-microorganisms-11-03004" ref-type="bibr">85</xref>,<xref rid="B86-microorganisms-11-03004" ref-type="bibr">86</xref>,<xref rid="B87-microorganisms-11-03004" ref-type="bibr">87</xref>,<xref rid="B88-microorganisms-11-03004" ref-type="bibr">88</xref>]. Relapses in such infections were not attributed to on-treatment moxifloxacin resistance, as opposed to when ciprofloxacin had been previously used as monotherapy [<xref rid="B85-microorganisms-11-03004" ref-type="bibr">85</xref>,<xref rid="B86-microorganisms-11-03004" ref-type="bibr">86</xref>,<xref rid="B89-microorganisms-11-03004" ref-type="bibr">89</xref>].</p></sec><sec><title>Rifampicin-Containing Regimens for <italic toggle="yes">S. aureus</italic> Bacteremia</title><p>Adjunctive rifampicin seems to be a reasonable approach in patients with bacteremia from rifampicin-susceptible strains who have a (yet uninfected) foreign body. Two post hoc analyses of INSTINCT cohort study showed that this subgroup had a significant reduction in bacteremia-related late complications and 90- and 180-day mortality when received a biofilm-acting agent like rifampicin, fluoroquinolone or fosfomycin as second antibiotic [<xref rid="B90-microorganisms-11-03004" ref-type="bibr">90</xref>,<xref rid="B91-microorganisms-11-03004" ref-type="bibr">91</xref>]. This result is strengthened by the observation that 68% of bacteremia-related late complications were foreign body-associated [<xref rid="B91-microorganisms-11-03004" ref-type="bibr">91</xref>]. Notably, moxifloxacin should not be combined with doxycycline against <italic toggle="yes">S. aureus</italic> because available data indicate antagonism between these drugs [<xref rid="B92-microorganisms-11-03004" ref-type="bibr">92</xref>]. </p></sec><sec><title>Streptococcal Bacteremia: Clinical Efficacy Data</title><p>Multiple retrospective studies have been published on streptococcal bacteremia regarding oral switch, too. More than two decades ago, a case series with 18 individuals hospitalized for bacteremic <italic toggle="yes">Streptococcus pneumoniae</italic> pneumonia with intact gastrointestinal absorption who underwent oral switch within the first week of hospitalization was published [<xref rid="B93-microorganisms-11-03004" ref-type="bibr">93</xref>]. All patients had been improved clinically before switch and no one experienced a failure [<xref rid="B93-microorganisms-11-03004" ref-type="bibr">93</xref>]. Moreover, data from a randomized trial comparing two amoxicillin/clavulanate oral formulations for community-acquired pneumonia show that 37 of these participants had bacteremic pneumonia from <italic toggle="yes">S. pneumoniae</italic> and received only oral antibiotics for the whole course of treatment; no worse outcomes were reported for this subgroup [<xref rid="B94-microorganisms-11-03004" ref-type="bibr">94</xref>]. </p><p>In a subsequent cohort of 244 patients with streptococcal bacteremia without endocarditis, concomitant bone and joint or central nervous system infection who had initial Pitt bacteremia scores &#8804; 3 and had already improved from IV treatment, 40% underwent oral de-escalation; no difference in 30-day recurrence, readmission, or mortality rate was observed [<xref rid="B95-microorganisms-11-03004" ref-type="bibr">95</xref>]. The most frequent sources of bacteremia were pneumonia and ABSSSI [<xref rid="B95-microorganisms-11-03004" ref-type="bibr">95</xref>]. Regardless of source or the causative species, oral step-down was performed after four days of IV therapy and total length of treatment was two weeks; this early switch reduced the duration of hospital stay by five days [<xref rid="B95-microorganisms-11-03004" ref-type="bibr">95</xref>]. Oral agents of choice were fluoroquinolones and secondarily amoxicillin, clindamycin, and TMP/SMX [<xref rid="B95-microorganisms-11-03004" ref-type="bibr">95</xref>]. Another two recently published cohorts with similar size, sources of bacteremia and timing of oral antibiotic initiation did not detect any significant differences in antibiotic-related adverse events and 90-day hospital readmission, treatment failure, or mortality between oral step-down and IV-only groups [<xref rid="B96-microorganisms-11-03004" ref-type="bibr">96</xref>,<xref rid="B97-microorganisms-11-03004" ref-type="bibr">97</xref>]. Reports with smaller number of patients almost reproduce the aforementioned results. Ramos-Otero et al. found that patients who received an oral regimen had significantly earlier hospital discharge without increased risk of recurrence or death in the same setting, irrespective of whether they received IV antibiotics for three days or more [<xref rid="B98-microorganisms-11-03004" ref-type="bibr">98</xref>]. </p><p>In addition, a multicenter study comparing oral step-down with fluoroquinolones or beta-lactams in a population consisting mostly of patients with pneumonia or ABSSSI with positive blood cultures was conducted [<xref rid="B99-microorganisms-11-03004" ref-type="bibr">99</xref>]. Beta-lactams were non-inferior to fluoroquinolones for the composite outcome of 90-day recurrence, readmission, or death; in both arms one of these complications occurred at &lt;10% of the cases [<xref rid="B99-microorganisms-11-03004" ref-type="bibr">99</xref>]. Oral step-down before day 3 was identified as a risk factor for clinical failure, although the median timing was 5.67 days; total treatment duration was again two weeks [<xref rid="B99-microorganisms-11-03004" ref-type="bibr">99</xref>]. On the other hand, regarding beta-hemolytic <italic toggle="yes">Streptococci</italic> in patients with ABSSSI-derived bacteremia, a study using propensity score-matched analysis could not confirm non-inferiority of oral switch to beta-lactams compared with IV antibiotics for the whole course of treatment, likely due to underdosing of oral antibiotics and the use of cefdinir, which has low bioavailability and consequently it is not an appropriate choice for bacteremia; treatment failure in both subgroups (low oral dosage and cefdinir use) was above 40% [<xref rid="B100-microorganisms-11-03004" ref-type="bibr">100</xref>].</p></sec><sec><title>Enterococcal Bacteremia: Clinical Efficacy Data</title><p>Regarding enterococcal bacteremia, ampicillin or amoxicillin should be the backbone of antimicrobial therapy if the causative strain is susceptible, because data from a retrospective cohort study conducted in Australia revealed that glycopeptide administration instead of beta-lactams was an independent risk factor for 30-day mortality [<xref rid="B101-microorganisms-11-03004" ref-type="bibr">101</xref>]. Notably, these results favored beta-lactams despite including in the cohort patients with endocarditis who were almost exclusively in the beta-lactam group; individuals in vancomycin arm were younger, too [<xref rid="B101-microorganisms-11-03004" ref-type="bibr">101</xref>]. These findings were in alignment with a subsequent retrospective study where 30-day mortality rate was higher in the vancomycin treatment group, even though a percentage of patients in the anti-enterococcal beta-lactam group were switched to oral amoxicillin at some point during treatment [<xref rid="B102-microorganisms-11-03004" ref-type="bibr">102</xref>]. It is unknown, however, whether these results suggest that ampicillin is truly superior compared with vancomycin or this is a consequence of vancomycin underdosing, which is frequent in the absence of TDM if a conventional 1 g bid dose is applied [<xref rid="B103-microorganisms-11-03004" ref-type="bibr">103</xref>]. </p><p>For infections caused by ampicillin-resistant strains, glycopeptides remain the first choice during initial management due to efficacy and lower cost. Linezolid, however, could also be administered, either in patients who experience adverse events from glycopeptides or as an oral step-down approach. Data from the previously mentioned randomized trial published by Wilcox et al., which included participants with enterococcal CRBSI, indicate that linezolid was non-inferior to vancomycin [<xref rid="B73-microorganisms-11-03004" ref-type="bibr">73</xref>]. Moreover, a small retrospective study from Spain found no significant difference in clinical or microbiological cure and 30-day mortality among patients with bacteremia caused by <italic toggle="yes">E. faecium</italic> treated with linezolid or glycopeptides [<xref rid="B104-microorganisms-11-03004" ref-type="bibr">104</xref>].</p><p>On the other hand, the optimal initial antimicrobial agent against vancomycin-resistant <italic toggle="yes">Enterococci</italic> (VRE) remains unknown due to the lack of high-quality data. A retrospective, propensity score-matched cohort study with 2630 patients who received linezolid or daptomycin for VRE bacteremia or endocarditis revealed that daptomycin group had lower mortality only for endocarditis; patients in daptomycin arm experienced fewer adverse effects, too [<xref rid="B105-microorganisms-11-03004" ref-type="bibr">105</xref>]. However, it should be noted that daptomycin was prescribed in a dose of approximately 6 mg/kg (not a high dose) [<xref rid="B105-microorganisms-11-03004" ref-type="bibr">105</xref>]. Furthermore, daptomycin MICs were not reported, which is the main factor that guides the optimal dose. EUCAST guidance and other publications suggest that if daptomycin MIC is &#8804;1 mg/L, a 6 mg/kg dose is efficacious [<xref rid="B106-microorganisms-11-03004" ref-type="bibr">106</xref>]. For an MIC above 1 mg/L, however, higher doses and probably combination with a beta-lactam are needed [<xref rid="B106-microorganisms-11-03004" ref-type="bibr">106</xref>,<xref rid="B107-microorganisms-11-03004" ref-type="bibr">107</xref>]. In a meta-analysis concerning only high-dose daptomycin versus linezolid, again no difference in mortality was observed, although patients who received daptomycin had a higher proportion of organ dysfunction and hematologic malignancy; thrombocytopenia was significantly more frequent in linezolid group [<xref rid="B108-microorganisms-11-03004" ref-type="bibr">108</xref>]. Regardless, oral de-escalation with linezolid seems like it could be implemented in any case.</p></sec><sec><title>Linezolid for Gram-Positive Bacteremia: PK/PD and TDM Data</title><p>Linezolid was prescribed as a fixed regimen of 600 mg bid in all the aforementioned studies, regardless of renal and hepatic function, as the drug summary of product characteristics indicates. These recommendations, however, are based on an older PK study where participants received only one 600 mg dose of linezolid orally [<xref rid="B109-microorganisms-11-03004" ref-type="bibr">109</xref>]. The truth is that linezolid is primary metabolized in the liver and a 30% of the dose undergoes renal elimination [<xref rid="B110-microorganisms-11-03004" ref-type="bibr">110</xref>]. This one-size fits all approach can lead to high interindividual variability observed by TDM, resulting in a proportion of patients treated with suboptimal doses and another percentage that is exposed to a high, myelotoxic dose. For that reason, linezolid TDM is suggested in critically ill patients and a Chinese expert consensus statement for linezolid dose optimization has been published in 2022 [<xref rid="B111-microorganisms-11-03004" ref-type="bibr">111</xref>,<xref rid="B112-microorganisms-11-03004" ref-type="bibr">112</xref>]. Data from a meta-analysis including 3580 patients who were prescribed linezolid revealed that eGFR &#8804; 50 mL/min raised the risk for thrombocytopenia more than two-fold, and the risk become even higher as kidney function worsened or hemodialysis was needed; renal impairment was a risk factor for linezolid-induced anemia, too [<xref rid="B113-microorganisms-11-03004" ref-type="bibr">113</xref>,<xref rid="B114-microorganisms-11-03004" ref-type="bibr">114</xref>]. In addition, a smaller retrospective study has showed that as eGFR declines, the incidence of linezolid discontinuation due to thrombocytopenia increases and, in many cases, it may start within the first week of treatment [<xref rid="B115-microorganisms-11-03004" ref-type="bibr">115</xref>]. This risk can be lowered if a dose of 300 mg bid is administered when eGFR &#8804; 60 mL/min, as PTA (trough linezolid levels &gt; 2 mg/L) was not different for this dosage compared with 600 mg bid in this subgroup according to retrospective TDM data, whereas the probability of potentially toxic trough levels (&gt;8 mg/L) was almost three times lower (<xref rid="microorganisms-11-03004-t002" ref-type="table">Table 2</xref>) [<xref rid="B116-microorganisms-11-03004" ref-type="bibr">116</xref>]. Similar dose reductions are suggested for severe hepatic impairment (<xref rid="microorganisms-11-03004-t002" ref-type="table">Table 2</xref>) [<xref rid="B112-microorganisms-11-03004" ref-type="bibr">112</xref>,<xref rid="B117-microorganisms-11-03004" ref-type="bibr">117</xref>]. On the other hand, PK/PD studies have indicated that PTA is very low when MIC is at the EUCAST breakpoint of 4 mg/L and therefore linezolid should be avoided, while PTA &gt; 85% was achieved only through continuous infusion in critically ill patients if MIC = 2 mg/L [<xref rid="B118-microorganisms-11-03004" ref-type="bibr">118</xref>,<xref rid="B119-microorganisms-11-03004" ref-type="bibr">119</xref>]. Appropriate dose modification should be applied for patients with obesity, too (see <xref rid="microorganisms-11-03004-t002" ref-type="table">Table 2</xref>) [<xref rid="B112-microorganisms-11-03004" ref-type="bibr">112</xref>,<xref rid="B119-microorganisms-11-03004" ref-type="bibr">119</xref>,<xref rid="B120-microorganisms-11-03004" ref-type="bibr">120</xref>].</p><table-wrap position="anchor" id="microorganisms-11-03004-t002" orientation="portrait"><object-id pub-id-type="pii">microorganisms-11-03004-t002_Table 2</object-id><label>Table 2</label><caption><p>Oral antibiotic dosages for bacteremia and infective endocarditis/non-beta-lactams.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Oral Antibiotic</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Microorganism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MIC<break/>(mg/L)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dosage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose Adjustment<break/>for Special Populations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ciprofloxacin</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Enterobacterales</italic>;<break/><italic toggle="yes">Pseudomonas</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">&#8804;0.125</td><td align="center" valign="middle" rowspan="1" colspan="1">500 mg bid</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">eGFR &#8804; 30 mL/min: 25% dose reduction<break/>Obesity: no dose modification</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B10-microorganisms-11-03004" ref-type="bibr">10</xref>,<xref rid="B56-microorganisms-11-03004" ref-type="bibr">56</xref>,<xref rid="B58-microorganisms-11-03004" ref-type="bibr">58</xref>,<xref rid="B121-microorganisms-11-03004" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">750 mg bid</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avoid</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Levofloxacin</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Enterobacterales</italic>;<break/><italic toggle="yes">Pseudomonas</italic>;<break/><italic toggle="yes">Streptococci</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">&#8804;1</td><td align="center" valign="middle" rowspan="1" colspan="1">Dose guided by creatinine clearance based on ideal body weight</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#8804;30 mL/min: 500 mg qd<break/>30&#8211;90 mL/min: 750 mg qd<break/>&gt;90 mL/min: 500 mg bid</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B122-microorganisms-11-03004" ref-type="bibr">122</xref>,<xref rid="B123-microorganisms-11-03004" ref-type="bibr">123</xref>,<xref rid="B124-microorganisms-11-03004" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avoid</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Moxifloxacin</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Enterobacterales</italic>; </td><td align="center" valign="middle" rowspan="1" colspan="1">&#8804;0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">400 mg qd</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Renal impairment or obesity: no dose modification</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B83-microorganisms-11-03004" ref-type="bibr">83</xref>,<xref rid="B84-microorganisms-11-03004" ref-type="bibr">84</xref>,<xref rid="B125-microorganisms-11-03004" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococci</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">Avoid</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococci</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8804;0.06</td><td align="center" valign="middle" rowspan="1" colspan="1">400 mg qd</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.125</td><td align="center" valign="middle" rowspan="1" colspan="1">Use in combination with another agent or 800 mg/day, preferably with TDM</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;0.125</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avoid</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">TMP/SMX</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Enterobacterales</italic>;<break/><italic toggle="yes">Streptococci</italic>;<break/><italic toggle="yes">Staphylococci</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">&#8804;1</td><td align="center" valign="middle" rowspan="1" colspan="1">10 mg/kg/day (TMP component)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">eGFR &#8804; 30 mL/min: 50% dose reduction</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B126-microorganisms-11-03004" ref-type="bibr">126</xref>,<xref rid="B127-microorganisms-11-03004" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(as TMP concentration [=20 mg/L TMP/SXT])</td><td align="center" valign="middle" rowspan="1" colspan="1">divided in 2&#8211;3 doses</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avoid</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Clindamycin</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Staphylococci</italic>;<break/><italic toggle="yes">Streptococci</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">&#8804;0.25</td><td align="center" valign="middle" rowspan="1" colspan="1">600 mg tid</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bone source of bacteremia<break/>and either body weight &gt;75 kg or MIC = 0.25 mg/L: 900 mg tid</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B70-microorganisms-11-03004" ref-type="bibr">70</xref>,<xref rid="B76-microorganisms-11-03004" ref-type="bibr">76</xref>,<xref rid="B77-microorganisms-11-03004" ref-type="bibr">77</xref>,<xref rid="B79-microorganisms-11-03004" ref-type="bibr">79</xref>,<xref rid="B128-microorganisms-11-03004" ref-type="bibr">128</xref>,<xref rid="B129-microorganisms-11-03004" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avoid</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Linezolid</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic toggle="yes">Staphylococci</italic>;<break/><italic toggle="yes">Streptococci</italic>;<break/><italic toggle="yes">Enterococci</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;2</td><td align="center" valign="middle" rowspan="1" colspan="1">600 mg bid</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">eGFR &#8804; 60 mL/min, Child-Pugh C cirrhosis or INR &gt; 2 due to hepatic impairment: 300 mg bid<break/>Dialysis-dependent<break/>patients:<break/>300 mg bid or 600 mg qd<break/>eGFR &#8805; 120 mL/min: avoid<break/>Obesity plus eGFR &#8804; 60 mL/min: 600 mg bid<break/>Obesity plus eGFR &#8805; 60 mL/min: 450 mg tid<break/>If body weight is &gt;140 kg, use only if MIC &#8804; 1 mg/L</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B112-microorganisms-11-03004" ref-type="bibr">112</xref>,<xref rid="B113-microorganisms-11-03004" ref-type="bibr">113</xref>,<xref rid="B116-microorganisms-11-03004" ref-type="bibr">116</xref>,<xref rid="B117-microorganisms-11-03004" ref-type="bibr">117</xref>,<xref rid="B118-microorganisms-11-03004" ref-type="bibr">118</xref>,<xref rid="B119-microorganisms-11-03004" ref-type="bibr">119</xref>,<xref rid="B120-microorganisms-11-03004" ref-type="bibr">120</xref>,<xref rid="B130-microorganisms-11-03004" ref-type="bibr">130</xref>,<xref rid="B131-microorganisms-11-03004" ref-type="bibr">131</xref>,<xref rid="B132-microorganisms-11-03004" ref-type="bibr">132</xref>,<xref rid="B133-microorganisms-11-03004" ref-type="bibr">133</xref>,<xref rid="B134-microorganisms-11-03004" ref-type="bibr">134</xref>,<xref rid="B135-microorganisms-11-03004" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Use in combination if possible or use TDM</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Avoid</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rifampicin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Staphylococci</italic>;<break/><italic toggle="yes">Streptococci</italic>;<break/><italic toggle="yes">Enterococci</italic><break/>(adjunct treatment)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8804;0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">300 mg tid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B136-microorganisms-11-03004" ref-type="bibr">136</xref>,<xref rid="B137-microorganisms-11-03004" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metronidazole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anaerobes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8804;4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Infections outside central nervous system:<break/>500 mg bid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Obesity:<break/>500 mg tid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-microorganisms-11-03004" ref-type="bibr">138</xref>,<xref rid="B139-microorganisms-11-03004" ref-type="bibr">139</xref>,<xref rid="B140-microorganisms-11-03004" ref-type="bibr">140</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>List of abbreviations: MIC, minimum inhibitory concentration; eGFR, estimated glomerular filtration rate; qd, once a day; bid, two times a day; tid, three times a day; INR, international normalized ratio; TDM, therapeutic drug monitoring; TMP, trimethoprim; SXT, sulfamethoxazole.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Oral Amoxicillin for Bacteremia: PK/PD Data</title><p>Although oral amoxicillin is widely used against enterococcal and streptococcal bacteremia, as well as in amoxicillin-sensitive <italic toggle="yes">Enterobacterales</italic> bacteremia, oral dosing regimens are nowhere near IV dosages of 100&#8211;200 mg/kg/day [<xref rid="B137-microorganisms-11-03004" ref-type="bibr">137</xref>]. The reason for this discrepancy is that such high doses are impossible to be absorbed from human gut due to the presence of a saturable, probably capacity-limited and carrier-mediated mechanism of transport from human intestine to circulation [<xref rid="B141-microorganisms-11-03004" ref-type="bibr">141</xref>]. A pharmacological study in healthy volunteers has revealed that amoxicillin oral bioavailability is dose-dependent; from almost 100% for a 375 mg dose to 55% for a 3000 mg dose, which in addition caused more gastrointestinal adverse effects [<xref rid="B141-microorganisms-11-03004" ref-type="bibr">141</xref>]. In alignment with these results, when amoxicillin was administered orally to individuals with an ileostomy, a 8% of amoxicillin was recovered from ileal fluid for a dose of 375 mg while for a 6000 mg dose a 77% recovery was observed, with the respective variations at the fraction excreted in urine (70% recovery at the lowest dose to 23% at the highest dose); these results have been reproduced in another study, too [<xref rid="B142-microorganisms-11-03004" ref-type="bibr">142</xref>,<xref rid="B143-microorganisms-11-03004" ref-type="bibr">143</xref>].</p><p>The aforementioned data play a pivotal role in the selection of patients with bacteremia or endocarditis that could be de-escalated to oral amoxicillin. A PK/PD study for pyelonephritis (where tissue and not urine antibiotic concentrations are relevant to cure) has showed that even for the modest target of 32.5%<italic toggle="yes">f</italic>T &gt; MIC, PTA is &lt;90% for a 1000 mg tid regimen when MIC is &gt; 2 mg/L, well below the established breakpoint of 8 mg/L for IV administration [<xref rid="B47-microorganisms-11-03004" ref-type="bibr">47</xref>,<xref rid="B144-microorganisms-11-03004" ref-type="bibr">144</xref>]. A recent publication claims that maybe lower doses (750 mg tid) are sufficient for 50%<italic toggle="yes">f</italic>T &gt; MIC if MIC &#8804; 2 mg/L (see also <xref rid="microorganisms-11-03004-t001" ref-type="table">Table 1</xref>) [<xref rid="B10-microorganisms-11-03004" ref-type="bibr">10</xref>]. The same model calculated that for an MIC of 8 mg/L, an oral dose of 2500 mg tid would be necessary, which is a regimen that, while it has not been tested on a large scale, could have many tolerance issues [<xref rid="B47-microorganisms-11-03004" ref-type="bibr">47</xref>]. Further evidence about the efficacy and tolerability of these higher amoxicillin doses will be provided by the awaited RODEO 2 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02701595">NCT02701595</ext-link>) for endocarditis, where 2000 mg tid oral regimens will be opted [<xref rid="B145-microorganisms-11-03004" ref-type="bibr">145</xref>]. This rationale extends to amoxicillin/clavulanate, too, because PK/PD data from healthy volunteers revealed that 40%<italic toggle="yes">f</italic>T &gt; MIC and &gt;97.5% PTA is achieved only if MIC &#8804; 1 mg/L for 500/125 mg qid and 1000/125 mg tid doses [<xref rid="B48-microorganisms-11-03004" ref-type="bibr">48</xref>]. These findings corroborated by the PK/PD study from Yamada et al.; 1000/125 mg tid dose had PTA &gt; 90% for 32.5%<italic toggle="yes">f</italic>T &gt; MIC only if MIC was &#8804;2 mg/L, and 500/125 mg tid regimen had similar effect only for strains with an MIC at or below 1 mg/L [<xref rid="B42-microorganisms-11-03004" ref-type="bibr">42</xref>].</p></sec></sec></sec><sec id="sec3dot2-microorganisms-11-03004"><title>3.2. Infective Endocarditis</title><sec id="sec3dot2dot1-microorganisms-11-03004"><title>3.2.1. Clinical Efficacy Data and Relevant Guidelines</title><p>Although parenteral-only antimicrobial therapy for endocarditis appeared as a &#8220;rule of medicine&#8221; for decades, a series with 35 cases of <italic toggle="yes">S. aureus</italic> endocarditis who received an oral antistaphylococcal penicillin or clindamycin after a mean of 16-day IV therapy has been published in 1980 [<xref rid="B146-microorganisms-11-03004" ref-type="bibr">146</xref>]. In addition, a randomized trial concerning oral treatment for right-sided staphylococcal endocarditis in people who inject drugs has been finished more than 27 years ago [<xref rid="B147-microorganisms-11-03004" ref-type="bibr">147</xref>]. In this study, oral ciprofloxacin-rifampicin combination treatment was used after five days of IV antibiotics, with good results. However, the results may overestimate the efficacy of this oral regimen in endocarditis because participants who had two or more positive sets of blood cultures with no other apparent source of infection were enrolled as endocarditis cases [<xref rid="B147-microorganisms-11-03004" ref-type="bibr">147</xref>]. Nowadays, VIRSTA and DENOVA scores can be applied to rule out endocarditis without cardiac ultrasound in some patients with bacteremia from <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Enterococcus faecalis</italic>, respectively [<xref rid="B148-microorganisms-11-03004" ref-type="bibr">148</xref>,<xref rid="B149-microorganisms-11-03004" ref-type="bibr">149</xref>,<xref rid="B150-microorganisms-11-03004" ref-type="bibr">150</xref>]. </p><p>Both the 2015 American and European guidelines for endocarditis had already adopted oral treatment for infections caused by typical bacteria, either as a drug-of-choice or as an alternative. In particular, linezolid (oral or IV) is one of the first-line regimens for endocarditis caused by <italic toggle="yes">Enterococci</italic> that are resistant to ampicillin and vancomycin [<xref rid="B136-microorganisms-11-03004" ref-type="bibr">136</xref>,<xref rid="B151-microorganisms-11-03004" ref-type="bibr">151</xref>]. The efficacy of oral linezolid in this setting had already been evaluated in a small number of cases since its first years on the market [<xref rid="B152-microorganisms-11-03004" ref-type="bibr">152</xref>,<xref rid="B153-microorganisms-11-03004" ref-type="bibr">153</xref>]. However, linezolid treatment for enterococcal endocarditis when the pathogen is resistant to vancomycin was associated with higher mortality and adverse event rate compared with daptomycin in a retrospective cohort; therefore, it should be reserved as an oral step-down choice after the initial IV treatment with a daptomycin-containing regimen, provided that MIC for daptomycin is not &gt;4 mg/L [<xref rid="B105-microorganisms-11-03004" ref-type="bibr">105</xref>,<xref rid="B107-microorganisms-11-03004" ref-type="bibr">107</xref>]. In addition, rifampicin (oral or IV) is included in the proposed regimen for staphylococcal prosthetic valve endocarditis at a dose of 300 mg tid [<xref rid="B136-microorganisms-11-03004" ref-type="bibr">136</xref>,<xref rid="B151-microorganisms-11-03004" ref-type="bibr">151</xref>].</p><p>Moreover, both American and European guidelines include IV or oral ciprofloxacin as an alternative treatment for HACEK endocarditis [<xref rid="B136-microorganisms-11-03004" ref-type="bibr">136</xref>,<xref rid="B151-microorganisms-11-03004" ref-type="bibr">151</xref>]. European guidelines also suggest the 1-week IV combination of TMP/SMX 4800/960 mg/day and clindamycin 600 mg tid, followed by oral TMP/SMX monotherapy as another option against staphylococcal endocarditis [<xref rid="B151-microorganisms-11-03004" ref-type="bibr">151</xref>]. This recommendation had been based on a preliminary report of the study published by Tissot-Dupont et al. in 2019 [<xref rid="B128-microorganisms-11-03004" ref-type="bibr">128</xref>]. In this study, all patients received this regimen except those who had positive blood cultures after the second day of treatment or in the cases where a cardiac abscess was present; in these two scenarios, IV rifampicin (1800 mg/day) and gentamicin (180 mg/day) were added for the first week [<xref rid="B128-microorganisms-11-03004" ref-type="bibr">128</xref>]. The outcomes of the participants in this protocol were compared with an older control group of patients treated in the same center for staphylococcal endocarditis with conventional IV regimens. Although the mean age was higher in the oral group, no statistical difference in 90-day mortality or relapse was found; mortality was not significantly different even after 1-year follow-up [<xref rid="B128-microorganisms-11-03004" ref-type="bibr">128</xref>]. To our opinion, further trials should be performed to assess the efficacy of clindamycin plus TMP/SMX for the whole course of treatment for endocarditis.</p><p>The publication, however, that brought the biggest changes in this setting at the recent 2023 European guidelines for endocarditis was POET trial and its sub-studies. This randomized, non-inferiority trial compared oral step-down with IV-only treatment in 400 participants with staphylococcal, enterococcal, or streptococcal left-sided endocarditis who had already received IV antibiotics for at least ten days (median 17 days) and for at least seven days after valve surgery, showed clinical and laboratory improvement, and had no indication of a local complication requiring surgery according to transesophageal echocardiography performed before randomization [<xref rid="B44-microorganisms-11-03004" ref-type="bibr">44</xref>]. Notably, enrollment included participants with prosthetic valve endocarditis or a permanent pacemaker [<xref rid="B44-microorganisms-11-03004" ref-type="bibr">44</xref>]. Oral de-escalation strategy, which consisted of two antibiotics with different mechanisms of action, was not inferior according to the 6-month composite outcome of mortality, unplanned cardiac surgery, embolic events, or relapse; these results were consistent during an extended follow-up after three and five years, too [<xref rid="B44-microorganisms-11-03004" ref-type="bibr">44</xref>,<xref rid="B154-microorganisms-11-03004" ref-type="bibr">154</xref>,<xref rid="B155-microorganisms-11-03004" ref-type="bibr">155</xref>]. Moreover, the oral group had a significantly shorter length of stay in the hospital [<xref rid="B44-microorganisms-11-03004" ref-type="bibr">44</xref>]. Before POET, a cohort study including 214 patients with endocarditis who underwent oral step-down had similar results; no increased risk of mortality or relapse was observed [<xref rid="B156-microorganisms-11-03004" ref-type="bibr">156</xref>]. Although de-escalation was applied later in-course of treatment in this cohort (mean after 14 days for <italic toggle="yes">Streptococci</italic> and 28 days for <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">Enterococci</italic>) it still reduced IV-treatment days substantially, given the fact that 23% of the cases had prosthetic valve endocarditis [<xref rid="B156-microorganisms-11-03004" ref-type="bibr">156</xref>]. Patients were eligible for oral treatment only if they were afebrile, laboratory and imaging abnormalities were improving, and blood cultures had been sterilized [<xref rid="B156-microorganisms-11-03004" ref-type="bibr">156</xref>]. Oral combination treatment was prescribed only against <italic toggle="yes">Staphylococci</italic> (mostly two of a fluoroquinolone, clindamycin, and rifampicin or combination of amoxicillin with one of them), whereas a strategy of amoxicillin monotherapy was almost totally adopted for <italic toggle="yes">Streptococci</italic> and <italic toggle="yes">Enterococci</italic> [<xref rid="B156-microorganisms-11-03004" ref-type="bibr">156</xref>].</p><p>The more commonly used oral regimens in POET trial were rifampicin 600 mg bid plus either amoxicillin or dicloxacillin 1 g qid for <italic toggle="yes">S. aureus</italic> (all cases were methicillin-sensitive), amoxicillin as backbone therapy plus one of rifampicin, moxifloxacin and linezolid against <italic toggle="yes">E. faecalis</italic>, and for <italic toggle="yes">Streptococcus</italic> spp. endocarditis, the aforementioned anti-enterococcal regimens were mainly prescribed, as well as a linezolid&#8211;rifampicin combination [<xref rid="B44-microorganisms-11-03004" ref-type="bibr">44</xref>]. All these findings led 2023 European Society of Cardiology guideline task force to adopt the rationale of POET study and to suggest oral step-down with two antibiotics from different drug classes, provided that all criteria applied in the study are fulfilled [<xref rid="B137-microorganisms-11-03004" ref-type="bibr">137</xref>]. Proposed regimens from the guidelines are similar to those used in POET.</p><p>Another oral antibiotic combination that, to our perspective, appears promising against endocarditis caused by <italic toggle="yes">E. faecalis</italic> is amoxicillin plus cefditoren, an &#8220;oral extrapolation&#8221; of the IV, guideline-proposed ampicillin&#8211;ceftriaxone regimen [<xref rid="B136-microorganisms-11-03004" ref-type="bibr">136</xref>,<xref rid="B137-microorganisms-11-03004" ref-type="bibr">137</xref>]. Attanasio et al. published a case series of five patients with <italic toggle="yes">E. faecalis</italic> prosthetic valve endocarditis who received amoxicillin/clavulanate 1 g tid plus cefditoren 400 mg bid as an oral regimen after a median of four weeks IV; no patients required surgery [<xref rid="B157-microorganisms-11-03004" ref-type="bibr">157</xref>].</p></sec><sec id="sec3dot2dot2-microorganisms-11-03004"><title>3.2.2. Considerations Regarding Oral Antibiotic Selection in Endocarditis</title><p>Notably, except the aforementioned combinations, guidelines also include regimens that did not tested thoroughly in the POET study like linezolid plus rifampicin for <italic toggle="yes">Staphylococci</italic> and <italic toggle="yes">Enterococci</italic> (two patients received it for this indication) and moxifloxacin plus rifampicin for <italic toggle="yes">Staphylococci</italic> and <italic toggle="yes">Streptococci</italic> (prescribed to three participants with staphylococcal endocarditis) [<xref rid="B44-microorganisms-11-03004" ref-type="bibr">44</xref>,<xref rid="B137-microorganisms-11-03004" ref-type="bibr">137</xref>]. Oral combination therapy with fucidic acid 750 mg bid is also included as a potential approach, although only six patients received it in POET [<xref rid="B44-microorganisms-11-03004" ref-type="bibr">44</xref>,<xref rid="B137-microorganisms-11-03004" ref-type="bibr">137</xref>]. </p><p>Like previously mentioned, moxifloxacin presents antagonism with doxycycline and moxifloxacin levels are reduced when co-administered with rifampicin; dramatic reduction in oral clindamycin bioavailability has also been observed if used with rifampicin. Okazaki et al. have reported reduced linezolid serum concentration when combined with rifampicin [<xref rid="B158-microorganisms-11-03004" ref-type="bibr">158</xref>]. Consequently, to our opinion, the aforementioned regimens should be avoided until further data are available. Even if linezolid&#8211;rifampicin co-administration has been effectively used for tuberculosis, that is a totally different context consisting of multidrug treatment against a microorganism that has substantially lower MIC for linezolid, so these data should not be extrapolated to endocarditis or bacteremia. Another drug class that should be used with extreme caution against <italic toggle="yes">S. aureus</italic> endocarditis is oral beta-lactams. This conclusion is derived from a PK/PD study based on TDM results from POET trial, where using a clinical breakpoint for staphylococci, the PTA for dicloxacillin was 9%&#8211;17% [<xref rid="B159-microorganisms-11-03004" ref-type="bibr">159</xref>]. A schematic illustration of the current antibiotic armamentarium depending on blood culture result is provided in <xref rid="microorganisms-11-03004-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec3dot2dot3-microorganisms-11-03004"><title>3.2.3. Probenecid as an Adjunct to Oral Beta-Lactams</title><p>A promising solution in improving the PTAs of oral beta-lactams is the addition of probenecid, a molecule that acts through competitive inhibition of organic anion transporters, which excrete beta-lactams from the kidneys. Probenecid remains a recommended adjunct against some sexually transmitted diseases like neurosyphilis [<xref rid="B160-microorganisms-11-03004" ref-type="bibr">160</xref>]. Moreover, oral amoxicillin can achieve treponemicidal levels in cerebrospinal fluid only when combined with probenecid [<xref rid="B161-microorganisms-11-03004" ref-type="bibr">161</xref>]. A systematic review and meta-analysis including data mainly from healthy volunteers suggested that when probenecid is added to an oral beta-lactam increases total AUC, maximum concentration and serum half-life, thus improving PTA [<xref rid="B162-microorganisms-11-03004" ref-type="bibr">162</xref>]. In particular, study results from a PK/PD model that was developed with data from co-administration of 1 g cefalexin with 500 mg of probenecid in 11 healthy individuals showed that PTA of %<italic toggle="yes">f</italic>T &gt; MIC &gt; 70% if MIC is 8 mg/L (epidemiological cut-off value (ECOFF) for <italic toggle="yes">S. aureus</italic>) rises from &lt;15% for cefalexin alone to almost 100% for a cefalexin 1 g qid regimen plus probenecid 500 mg bid [<xref rid="B43-microorganisms-11-03004" ref-type="bibr">43</xref>]. If MIC is &#8804;4 mg/L, then a regimen of cefalexin 1 g tid plus probenecid seemed sufficient [<xref rid="B43-microorganisms-11-03004" ref-type="bibr">43</xref>]. Administration with food and maybe even smaller doses of probenecid in cases of renal impairment can reduce probability for drug-induced nausea or other gastrointestinal adverse events [<xref rid="B43-microorganisms-11-03004" ref-type="bibr">43</xref>]. In comparison, PTA &gt; 90% was achieved if MIC was &#8804;1.5 and &#8804;3 mg/L for oral cefalexin alone when administered as 1 g tid and 1 g qid regimen, respectively [<xref rid="B43-microorganisms-11-03004" ref-type="bibr">43</xref>].</p></sec><sec id="sec3dot2dot4-microorganisms-11-03004"><title>3.2.4. Infective Endocarditis&#8212;Upcoming Trials</title><p>There is no doubt that further randomized trials are needed for bacterial endocarditis in order to solidify the evidence about the timing of oral switch and the proper oral regimens against each microorganism. The RODEO 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02701608">NCT02701608</ext-link>) and RODEO 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02701595">NCT02701595</ext-link>) trials for left-sided endocarditis caused by <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">Streptococcus</italic>/<italic toggle="yes">Enterococcus</italic> spp., respectively, are in the recruitment phase [<xref rid="B145-microorganisms-11-03004" ref-type="bibr">145</xref>]. Oral treatment will be attempted in both studies after a minimum of ten days IV therapy. Oral levofloxacin&#8211;rifampicin combination will be studied in RODEO 1 and oral amoxicillin in high doses (1500 mg tid for patients &#8804;70 kg and 2000 mg tid for patients &gt;70 kg) in RODEO 2 [<xref rid="B145-microorganisms-11-03004" ref-type="bibr">145</xref>]. In addition, another trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04544306">NCT04544306</ext-link>) examining non-inferiority of oral treatment after at least a 10-day IV regimen for endocarditis in people who inject drugs is recruiting participants [<xref rid="B163-microorganisms-11-03004" ref-type="bibr">163</xref>].</p></sec><sec id="sec3dot2dot5-microorganisms-11-03004"><title>3.2.5. The Potential Utility of Oral Fosfomycin against Endocarditis and Bacteremia</title><p>Fosfomycin is a hydrophilic antibiotic with small molecular mass which has negligible protein binding and consequently has good tissue distribution (see also <xref rid="microorganisms-11-03004-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B164-microorganisms-11-03004" ref-type="bibr">164</xref>,<xref rid="B165-microorganisms-11-03004" ref-type="bibr">165</xref>]. In addition, it seems that it has some yet unclear PK/PD properties [<xref rid="B166-microorganisms-11-03004" ref-type="bibr">166</xref>]. Time-dependent killing has been identified against <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">S. pyogenes</italic>, whereas concentration-dependent activity has been found against <italic toggle="yes">E. coli</italic> and <italic toggle="yes">Proteus</italic> [<xref rid="B167-microorganisms-11-03004" ref-type="bibr">167</xref>,<xref rid="B168-microorganisms-11-03004" ref-type="bibr">168</xref>,<xref rid="B169-microorganisms-11-03004" ref-type="bibr">169</xref>].</p><p>IV fosfomycin has already shown its effectiveness in the context of bacteremia and endocarditis. It was non-inferior to piperacillin/tazobactam as monotherapy in ZEUS trial which enrolled cases with complicated UTI, including patients with concomitant bacteremia [<xref rid="B170-microorganisms-11-03004" ref-type="bibr">170</xref>]. Fosfomycin has also showed synergistic effects with many antimicrobials and for that reason antibiotic combinations including fosfomycin are therapeutic options for staphylococcal and enterococcal endocarditis [<xref rid="B137-microorganisms-11-03004" ref-type="bibr">137</xref>]. Moreover, it can act against infections where biofilm formation is involved (e.g., prosthetic joint infections, prosthetic valve endocarditis) [<xref rid="B90-microorganisms-11-03004" ref-type="bibr">90</xref>,<xref rid="B91-microorganisms-11-03004" ref-type="bibr">91</xref>,<xref rid="B137-microorganisms-11-03004" ref-type="bibr">137</xref>]. </p><p>When the linezolid&#8211;fosfomycin combination was used at clinical isolates of <italic toggle="yes">Enterococcus</italic>, it prevented the emergence of resistant mutants in lower drug concentrations and was synergistic in a hollow fiber model; another in vitro study demonstrated a reduction in linezolid MIC when co-administered with fosfomycin, even though MICs for fosfomycin were relatively high (&#8805;64 mg/L) [<xref rid="B171-microorganisms-11-03004" ref-type="bibr">171</xref>,<xref rid="B172-microorganisms-11-03004" ref-type="bibr">172</xref>,<xref rid="B173-microorganisms-11-03004" ref-type="bibr">173</xref>]. The simulated fosfomycin regimen in this work, however, was higher than the levels achievable by oral administration [<xref rid="B171-microorganisms-11-03004" ref-type="bibr">171</xref>]. In addition, an in vitro study showed that the fosfomycin&#8211;cefixime combination has synergistic killing properties against <italic toggle="yes">E. coli</italic>, even in half the MIC concentrations for each drug [<xref rid="B174-microorganisms-11-03004" ref-type="bibr">174</xref>].</p><p>Oral fosfomycin trometamol exhibits a 33&#8211;44% bioavailability [<xref rid="B166-microorganisms-11-03004" ref-type="bibr">166</xref>,<xref rid="B175-microorganisms-11-03004" ref-type="bibr">175</xref>,<xref rid="B176-microorganisms-11-03004" ref-type="bibr">176</xref>,<xref rid="B177-microorganisms-11-03004" ref-type="bibr">177</xref>]. This characteristic has precluded its use for infections outside urinary tract until now. To date, clinical data from oral fosfomycin in this context do not exist. Khatri et al. reported two cases with persistent VRE bacteremia in neutropenic patients despite a multiple antibiotic treatment regimen that resolved only when oral fosfomycin in conventional doses was added [<xref rid="B178-microorganisms-11-03004" ref-type="bibr">178</xref>]. According to a population PK model, oral fosfomycin in higher doses than 3 g qd should be studied as a potential therapy for the treatment of systemic infections [<xref rid="B179-microorganisms-11-03004" ref-type="bibr">179</xref>]. This model indicates that an oral dose of 3 g tid can achieve the time and concentration-dependent targets for gram-positives, <italic toggle="yes">E. coli</italic> and <italic toggle="yes">Proteus</italic> if MIC &#8804; 8 mg/L [<xref rid="B179-microorganisms-11-03004" ref-type="bibr">179</xref>]. The simulation for an even higher oral dose (6 g TID) revealed a %<italic toggle="yes">f</italic>T &gt; MIC of 100% for MICs &#8804; 16 mg/L and a maximum concentration &gt;4 x MIC even for MICs above 8 mg/L (e.g., 12 mg/L) [<xref rid="B179-microorganisms-11-03004" ref-type="bibr">179</xref>].</p><fig position="anchor" id="microorganisms-11-03004-f002" orientation="portrait"><label>Figure 2</label><caption><p>Chemical structure of certain commonly used oral antibiotics (adapted from PubChem): (<bold>A</bold>), amoxicillin; (<bold>B</bold>), cloxacillin sodium; (<bold>C</bold>), cefalexin; (<bold>D</bold>), cefuroxime axetil; (<bold>E</bold>), cefixime; (<bold>F</bold>), ciprofloxacin hydrochloride; (<bold>G</bold>), levofloxacin hemihydrate; (<bold>H</bold>), moxifloxacin hydrochloride; (<bold>I</bold>) sulfamethoxazole/trimethoprim; (<bold>J</bold>), clindamycin; (<bold>K</bold>) linezolid; (<bold>L</bold>) fosfomycin trometamol [<xref rid="B180-microorganisms-11-03004" ref-type="bibr">180</xref>,<xref rid="B181-microorganisms-11-03004" ref-type="bibr">181</xref>,<xref rid="B182-microorganisms-11-03004" ref-type="bibr">182</xref>,<xref rid="B183-microorganisms-11-03004" ref-type="bibr">183</xref>,<xref rid="B184-microorganisms-11-03004" ref-type="bibr">184</xref>,<xref rid="B185-microorganisms-11-03004" ref-type="bibr">185</xref>,<xref rid="B186-microorganisms-11-03004" ref-type="bibr">186</xref>,<xref rid="B187-microorganisms-11-03004" ref-type="bibr">187</xref>,<xref rid="B188-microorganisms-11-03004" ref-type="bibr">188</xref>,<xref rid="B189-microorganisms-11-03004" ref-type="bibr">189</xref>,<xref rid="B190-microorganisms-11-03004" ref-type="bibr">190</xref>,<xref rid="B191-microorganisms-11-03004" ref-type="bibr">191</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="microorganisms-11-03004-g002.jpg"/></fig></sec></sec></sec><sec sec-type="conclusions" id="sec4-microorganisms-11-03004"><title>4. Conclusions</title><p>In summary, it seems like the available data, although the majority of them are non-randomized, are too significant to ignore; they suggest that, when a patient with bacteremia has received IV antibiotics and has improved, then it is safe and effective to de-escalate&#8212;after appropriate source control&#8212;to oral antibiotics, which have been shown to achieve their PK/PD target in serum. This strategy can reduce patient discomfort, hospital-associated complications, and costs. Until now, examples where IV therapy should be extended are concomitant bone infection and endocarditis, but even these cases can be safely switched after 7 and 10 days IV, respectively, based on randomized studies. It is yet unknown what the optimal approach should be to an individual who has a community-acquired infection but does not meet criteria for hospital admission, so empiric oral antibiotic treatment is prescribed, and subsequently blood cultures turn positive. Based on the scarce aforementioned data concerning oral-only regimens against bacteremia, if the clinical condition remains good, then an outpatient therapy could be tried with close follow-up examinations, but this is definitely a matter for debate. It is a fact that there are still many unanswered questions regarding antibiotic selection, the choice of monotherapy or combination treatment, antibiotic dosage, the timing of the oral switch, and the total days of treatment that future trials could focus on and consequently lead more physicians to implement this concept into their everyday practice.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, G.E. and S.F.A.; methodology, G.E. and S.F.A.; investigation, G.E., M.L. and S.F.A.; writing&#8212;original draft preparation, G.E.; writing&#8212;review and editing, M.M., S.B. and S.F.A.; supervision, M.M., S.B. and S.F.A. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-microorganisms-11-03004"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hospenthal</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Beekmann</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Polgreen</surname><given-names>P.M.</given-names></name></person-group><article-title>Practice Patterns of Infectious Diseases Physicians in Transitioning From Intravenous to Oral Therapy in Patients With Bacteremia</article-title><source>Open Forum Infect. Dis.</source><year>2020</year><volume>7</volume><fpage>ofz386</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofz386</pub-id><pub-id pub-id-type="pmid">33335941</pub-id><pub-id pub-id-type="pmcid">PMC7731529</pub-id></element-citation></ref><ref id="B2-microorganisms-11-03004"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thaden</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Tamma</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Doi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Daneman</surname><given-names>N.</given-names></name></person-group><article-title>Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections</article-title><source>Int. J. Antimicrob. Agents</source><year>2021</year><volume>58</volume><fpage>106451</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2021.106451</pub-id><pub-id pub-id-type="pmid">34653617</pub-id><pub-id pub-id-type="pmcid">PMC8645249</pub-id></element-citation></ref><ref id="B3-microorganisms-11-03004"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Thiemann</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>C.U.</given-names></name></person-group><article-title>Budget impact analysis of conversion from intravenous to oral medication when clinically eligible for oral intake</article-title><source>Clin. Ther.</source><year>2011</year><volume>33</volume><fpage>1792</fpage><lpage>1796</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2011.09.030</pub-id><pub-id pub-id-type="pmid">22001356</pub-id></element-citation></ref><ref id="B4-microorganisms-11-03004"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amodio-Groton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Madu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Madu</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Briceland</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Seligman</surname><given-names>M.</given-names></name><name name-style="western"><surname>McMaster</surname><given-names>P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.H.</given-names></name></person-group><article-title>Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: A pharmacoeconomic analysis</article-title><source>Ann. Pharmacother.</source><year>1996</year><volume>30</volume><fpage>596</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1177/106002809603000605</pub-id><pub-id pub-id-type="pmid">8792944</pub-id></element-citation></ref><ref id="B5-microorganisms-11-03004"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shrestha</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Everett</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>S.J.</given-names></name></person-group><article-title>Vascular access complications during outpatient parenteral antimicrobial therapy at home: A retrospe ctive cohort study</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>506</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv344</pub-id><pub-id pub-id-type="pmid">26510718</pub-id></element-citation></ref><ref id="B6-microorganisms-11-03004"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keller</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gavgani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>D.</given-names></name><name name-style="western"><surname>Adamovich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hohl</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gurses</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>S.E.</given-names></name></person-group><article-title>Rates of and Risk Factors for Adverse Drug Events in Outpatient Parenteral Antimicrobial Therapy</article-title><source>Clin. Infect. Dis.</source><year>2018</year><volume>66</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1093/cid/cix733</pub-id><pub-id pub-id-type="pmid">29020202</pub-id><pub-id pub-id-type="pmcid">PMC5848264</pub-id></element-citation></ref><ref id="B7-microorganisms-11-03004"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Clarivet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lotth&#233;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bommart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parer</surname><given-names>S.</given-names></name></person-group><article-title>Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: A prospective cohort study</article-title><source>Antimicrob. Resist. Infect. Control</source><year>2017</year><volume>6</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/s13756-016-0161-0</pub-id><pub-id pub-id-type="pmid">28149507</pub-id><pub-id pub-id-type="pmcid">PMC5273851</pub-id></element-citation></ref><ref id="B8-microorganisms-11-03004"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krein</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Saint</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trautner</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Colozzi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ratz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lescinskas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>V.</given-names></name></person-group><article-title>Patient-reported complications related to peripherally inserted central catheters: A multicentre prospective cohort study</article-title><source>BMJ Qual. Saf.</source><year>2019</year><volume>28</volume><fpage>574</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1136/bmjqs-2018-008726</pub-id><pub-id pub-id-type="pmcid">PMC6593651</pub-id><pub-id pub-id-type="pmid">30683751</pub-id></element-citation></ref><ref id="B9-microorganisms-11-03004"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Krohe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mazar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Horsfield</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pompilus</surname><given-names>F.</given-names></name><name name-style="western"><surname>Friebe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shields</surname><given-names>A.L.</given-names></name></person-group><article-title>Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: A review of the literature</article-title><source>Patient Prefer. Adherence</source><year>2016</year><volume>10</volume><fpage>1609</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.2147/ppa.S106629</pub-id><pub-id pub-id-type="pmid">27601886</pub-id><pub-id pub-id-type="pmcid">PMC5003561</pub-id></element-citation></ref><ref id="B10-microorganisms-11-03004"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Den Broek</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Visser</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Veenstra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Den Berg</surname><given-names>B.T.J.</given-names></name><name name-style="western"><surname>Prins</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Van Hest</surname><given-names>R.M.</given-names></name></person-group><article-title>The effect of the acute phase of infection on absorption of and exposure to orally administered antibiotics in non-critically ill, hospitalized patients</article-title><source>J. Antimicrob. Chemother.</source><year>2023</year><volume>78</volume><fpage>389</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1093/jac/dkac401</pub-id><pub-id pub-id-type="pmid">36433818</pub-id><pub-id pub-id-type="pmcid">PMC9890209</pub-id></element-citation></ref><ref id="B11-microorganisms-11-03004"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gasparetto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tuon</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Dos Santos Oliveira</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zequinao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pipolo</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Beninc&#225;</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>J.A.W.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>T.P.</given-names></name></person-group><article-title>Intravenous-to-oral antibiotic switch therapy: A cross-sectional study in critical care units</article-title><source>BMC Infect. Dis.</source><year>2019</year><volume>19</volume><elocation-id>650</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-019-4280-0</pub-id><pub-id pub-id-type="pmid">31331272</pub-id><pub-id pub-id-type="pmcid">PMC6647098</pub-id></element-citation></ref><ref id="B12-microorganisms-11-03004"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rebuck</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Fish</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>E.</given-names></name></person-group><article-title>Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit</article-title><source>Pharmacotherapy</source><year>2002</year><volume>22</volume><fpage>1216</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1592/phco.22.15.1216.33484</pub-id><pub-id pub-id-type="pmid">12389872</pub-id></element-citation></ref><ref id="B13-microorganisms-11-03004"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thurber</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Dierkhising</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Sampathkumar</surname><given-names>P.</given-names></name></person-group><article-title>Comparison of intravenous and oral definitive antibiotic regimens in hospitalised patients with Gram-negative bacteraemia from a urinary tract infection</article-title><source>J. Glob. Antimicrob. Resist.</source><year>2019</year><volume>18</volume><fpage>243</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2019.03.013</pub-id><pub-id pub-id-type="pmid">30926468</pub-id></element-citation></ref><ref id="B14-microorganisms-11-03004"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamma</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Conley</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Lautenbach</surname><given-names>E.</given-names></name><name name-style="western"><surname>Amoah</surname><given-names>J.</given-names></name><name name-style="western"><surname>Avdic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tolomeo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wise</surname><given-names>J.</given-names></name><name name-style="western"><surname>Subudhi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia</article-title><source>JAMA Intern. Med.</source><year>2019</year><volume>179</volume><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2018.6226</pub-id><pub-id pub-id-type="pmid">30667477</pub-id><pub-id pub-id-type="pmcid">PMC6439703</pub-id></element-citation></ref><ref id="B15-microorganisms-11-03004"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rieger</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Bosso</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>MacVane</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Temple</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wahlquist</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bohm</surname><given-names>N.</given-names></name></person-group><article-title>Intravenous-only or Intravenous Transitioned to Oral Antimicrobials for Enterobacteriaceae-Associated Bacteremic Urinary Tract Infection</article-title><source>Pharmacotherapy</source><year>2017</year><volume>37</volume><fpage>1479</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1002/phar.2024</pub-id><pub-id pub-id-type="pmid">28869655</pub-id><pub-id pub-id-type="pmcid">PMC5681413</pub-id></element-citation></ref><ref id="B16-microorganisms-11-03004"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nisly</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>McClain</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Fillius</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>K.A.</given-names></name></person-group><article-title>Oral antibiotics for the treatment of Gram-negative bloodstream infections: A retrospective comparison of three antibiotic classes</article-title><source>J. Glob. Antimicrob. Resist.</source><year>2020</year><volume>20</volume><fpage>74</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2019.07.026</pub-id><pub-id pub-id-type="pmid">31390537</pub-id></element-citation></ref><ref id="B17-microorganisms-11-03004"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jayachandran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>K.</given-names></name></person-group><article-title>Clinical Impact of Oral Step-Down Therapy for Gram-Negative Bacteremia: A Retrospective Study</article-title><source>HCA Healthc. J. Med.</source><year>2023</year><volume>4</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.36518/2689-0216.1399</pub-id><pub-id pub-id-type="pmid">37424971</pub-id><pub-id pub-id-type="pmcid">PMC10324867</pub-id></element-citation></ref><ref id="B18-microorganisms-11-03004"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McAteer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Dzintars</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fiawoo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heil</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Kendall</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Louie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Malani</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Nori</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Defining the Optimal Duration of Therapy for Hospitalized Patients With Complicated Urinary Tract Infections and Associated Bacteremia</article-title><source>Clin. Infect. Dis.</source><year>2023</year><volume>76</volume><fpage>1604</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1093/cid/ciad009</pub-id><pub-id pub-id-type="pmid">36633559</pub-id><pub-id pub-id-type="pmcid">PMC10411929</pub-id></element-citation></ref><ref id="B19-microorganisms-11-03004"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutton</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>V.W.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Khader</surname><given-names>K.</given-names></name><name name-style="western"><surname>Timbrook</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Spivak</surname><given-names>E.S.</given-names></name></person-group><article-title>Oral &#946;-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source</article-title><source>JAMA Netw. Open</source><year>2020</year><volume>3</volume><fpage>e2020166</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.20166</pub-id><pub-id pub-id-type="pmid">33030555</pub-id><pub-id pub-id-type="pmcid">PMC7545306</pub-id></element-citation></ref><ref id="B20-microorganisms-11-03004"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tossey</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>El Boghdadly</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Dela-Pena</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Wardlow</surname><given-names>L.C.</given-names></name></person-group><article-title>Oral fluoroquinolones for definitive treatment of gram-negative bacteremia in cancer patients</article-title><source>Support Care Cancer</source><year>2021</year><volume>29</volume><fpage>5057</fpage><lpage>5064</lpage><pub-id pub-id-type="doi">10.1007/s00520-021-06063-6</pub-id><pub-id pub-id-type="pmid">33594513</pub-id></element-citation></ref><ref id="B21-microorganisms-11-03004"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Do</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H.C.</given-names></name></person-group><article-title>Early oral antibiotic switch compared with conventional intravenous antibiotic therapy for acute cholangitis with bacteremia</article-title><source>Dig. Dis. Sci.</source><year>2014</year><volume>59</volume><fpage>2790</fpage><lpage>2796</lpage><pub-id pub-id-type="doi">10.1007/s10620-014-3233-0</pub-id><pub-id pub-id-type="pmid">24898101</pub-id></element-citation></ref><ref id="B22-microorganisms-11-03004"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mack</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hiles</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wrin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>A.</given-names></name></person-group><article-title>Use of Fluoroquinolones or Sulfamethoxazole-Trimethoprim Compared to &#914;-Lactams for Oral Step-Down Therapy in Hospitalized Patients With Uncomplicated Enterobacterales Bacteremia</article-title><source>Ann. Pharmacother.</source><year>2023</year><volume>57</volume><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1177/10600280221106789</pub-id><pub-id pub-id-type="pmid">35758168</pub-id></element-citation></ref><ref id="B23-microorganisms-11-03004"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercuro</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Stogsdill</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wungwattana</surname><given-names>M.</given-names></name></person-group><article-title>Retrospective analysis comparing oral stepdown therapy for enterobacteriaceae bloodstream infections: Fluoroquinolones versus &#946;-lactams</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>51</volume><fpage>687</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.12.007</pub-id><pub-id pub-id-type="pmid">29284155</pub-id></element-citation></ref><ref id="B24-microorganisms-11-03004"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yahav</surname><given-names>D.</given-names></name><name name-style="western"><surname>Franceschini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koppel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Turjeman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Babich</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bitterman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Neuberger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghanem-Zoubi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Santoro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eliakim-Raz</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial</article-title><source>Clin. Infect. Dis.</source><year>2019</year><volume>69</volume><fpage>1091</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy1054</pub-id><pub-id pub-id-type="pmid">30535100</pub-id></element-citation></ref><ref id="B25-microorganisms-11-03004"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mombelli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pezzoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pinoja-Lutz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Monotti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Franciolli</surname><given-names>M.</given-names></name></person-group><article-title>Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: A prospective randomized clinical trial</article-title><source>Arch. Intern. Med.</source><year>1999</year><volume>159</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1001/archinte.159.1.53</pub-id><pub-id pub-id-type="pmid">9892331</pub-id></element-citation></ref><ref id="B26-microorganisms-11-03004"><label>26.</label><element-citation publication-type="gov"><article-title>Switch to Oral Antibiotics in Gram-Negative Bacteremia (SOAB); A Randomized, Open-Label, Clinical Trial</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT04146922#more-information" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04146922#more-information</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-11-11">(accessed on 11 November 2023)</date-in-citation></element-citation></ref><ref id="B27-microorganisms-11-03004"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>S.Y.C.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Paterson</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Syed-Omar</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Peck</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Cooke</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Libau</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>S.B.A.</given-names></name><etal/></person-group><article-title>Early oral stepdown antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial): Study protocol for a multicentre, randomised controlled, open-label, phase III, non-inferiority trial</article-title><source>Trials</source><year>2022</year><volume>23</volume><fpage>572</fpage><pub-id pub-id-type="doi">10.1186/s13063-022-06495-3</pub-id><pub-id pub-id-type="pmid">35854360</pub-id><pub-id pub-id-type="pmcid">PMC9295110</pub-id></element-citation></ref><ref id="B28-microorganisms-11-03004"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obaro</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Hassan-Hanga</surname><given-names>F.</given-names></name><name name-style="western"><surname>Olateju</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Umoru</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Olanipekun</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Munir</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ihesiolor</surname><given-names>G.</given-names></name><name name-style="western"><surname>Maduekwe</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Salmonella Bacteremia Among Children in Central and Northwest Nigeria, 2008-2015</article-title><source>Clin. Infect. Dis.</source><year>2015</year><volume>61</volume><issue>(Suppl. S4)</issue><fpage>S325</fpage><lpage>S331</lpage><pub-id pub-id-type="doi">10.1093/cid/civ745</pub-id><pub-id pub-id-type="pmid">26449948</pub-id><pub-id pub-id-type="pmcid">PMC4596937</pub-id></element-citation></ref><ref id="B29-microorganisms-11-03004"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuehn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stoesser</surname><given-names>N.</given-names></name><name name-style="western"><surname>Eyre</surname><given-names>D.</given-names></name><name name-style="western"><surname>Darton</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Basnyat</surname><given-names>B.</given-names></name><name name-style="western"><surname>Parry</surname><given-names>C.M.</given-names></name></person-group><article-title>Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins</article-title><source>Cochrane Database Syst. Rev.</source><year>2022</year><volume>11</volume><fpage>Cd010452</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD010452.pub2</pub-id><pub-id pub-id-type="pmid">36420914</pub-id><pub-id pub-id-type="pmcid">PMC9686137</pub-id></element-citation></ref><ref id="B30-microorganisms-11-03004"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhutta</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Molla</surname><given-names>A.M.</given-names></name></person-group><article-title>Therapy of multidrug-resistant typhoid fever with oral cefixime vs. intravenous ceftriaxone</article-title><source>Pediatr. Infect. Dis. J.</source><year>1994</year><volume>13</volume><fpage>990</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1097/00006454-199411000-00010</pub-id><pub-id pub-id-type="pmid">7845753</pub-id></element-citation></ref><ref id="B31-microorganisms-11-03004"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girgis</surname><given-names>N.I.</given-names></name><name name-style="western"><surname>Tribble</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Sultan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Farid</surname><given-names>Z.</given-names></name></person-group><article-title>Short course chemotherapy with cefixime in children with multidrug-resistant Salmonella typhi Septicaemia</article-title><source>J. Trop. Pediatr.</source><year>1995</year><volume>41</volume><fpage>364</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1093/tropej/41.6.364</pub-id><pub-id pub-id-type="pmid">8606446</pub-id></element-citation></ref><ref id="B32-microorganisms-11-03004"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vardakas</surname><given-names>K.Z.</given-names></name><name name-style="western"><surname>Tansarli</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Rafailidis</surname><given-names>P.I.</given-names></name><name name-style="western"><surname>Falagas</surname><given-names>M.E.</given-names></name></person-group><article-title>Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum &#946;-lactamases: A systematic review and meta-analysis</article-title><source>J. Antimicrob. Chemother.</source><year>2012</year><volume>67</volume><fpage>2793</fpage><lpage>2803</lpage><pub-id pub-id-type="doi">10.1093/jac/dks301</pub-id><pub-id pub-id-type="pmid">22915465</pub-id></element-citation></ref><ref id="B33-microorganisms-11-03004"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meije</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pigrau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Hidalgo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Clemente</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sanz</surname><given-names>X.</given-names></name><name name-style="western"><surname>Loureiro-Amigo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sierra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ayestar&#225;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morales-Cartagena</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum &#946;-lactamase (ESBL) or AmpC &#946;-lactamase: A propensity score study</article-title><source>Int. J. Antimicrob. Agents</source><year>2019</year><volume>54</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2019.05.004</pub-id><pub-id pub-id-type="pmid">31075401</pub-id></element-citation></ref><ref id="B34-microorganisms-11-03004"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brigmon</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Bookstaver</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Kohn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Albrecht</surname><given-names>H.</given-names></name><name name-style="western"><surname>Al-Hasan</surname><given-names>M.N.</given-names></name></person-group><article-title>Impact of fluoroquinolone resistance in Gram-negative bloodstream infections on healthcare utilization</article-title><source>Clin. Microbiol. Infect.</source><year>2015</year><volume>21</volume><fpage>843</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2015.05.013</pub-id><pub-id pub-id-type="pmid">26003282</pub-id></element-citation></ref><ref id="B35-microorganisms-11-03004"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shehab</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lovegrove</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Geller</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Weidle</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Budnitz</surname><given-names>D.S.</given-names></name></person-group><article-title>US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014</article-title><source>JAMA</source><year>2016</year><volume>316</volume><fpage>2115</fpage><lpage>2125</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.16201</pub-id><pub-id pub-id-type="pmid">27893129</pub-id><pub-id pub-id-type="pmcid">PMC6490178</pub-id></element-citation></ref><ref id="B36-microorganisms-11-03004"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjork</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cadena</surname><given-names>J.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>E.</given-names></name><name name-style="western"><surname>Frei</surname><given-names>C.R.</given-names></name></person-group><article-title>Comparative-Effectiveness of Oral Beta-Lactams and Fluoroquinolones for Stepdown Therapy in Patients with Enterobacterales Bloodstream Infections: A Retrospective Cohort Study</article-title><source>Int. J. Med. Sci.</source><year>2023</year><volume>20</volume><fpage>437</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.7150/ijms.80621</pub-id><pub-id pub-id-type="pmid">37057217</pub-id><pub-id pub-id-type="pmcid">PMC10087635</pub-id></element-citation></ref><ref id="B37-microorganisms-11-03004"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mina</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Afra</surname><given-names>K.</given-names></name></person-group><article-title>Oral beta-lactam step down in bacteremic E. coli urinary tract infections</article-title><source>BMC Infect. Dis.</source><year>2020</year><volume>20</volume><elocation-id>785</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-020-05498-2</pub-id><pub-id pub-id-type="pmid">33087051</pub-id><pub-id pub-id-type="pmcid">PMC7576740</pub-id></element-citation></ref><ref id="B38-microorganisms-11-03004"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mponponsuo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Fridman</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Johnstone</surname><given-names>J.</given-names></name><name name-style="western"><surname>Langford</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>MacFadden</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Daneman</surname><given-names>N.</given-names></name></person-group><article-title>Highly versus less bioavailable oral antibiotics in the treatment of gram-negative bloodstream infections: A propensity-matched cohort analysis</article-title><source>Clin. Microbiol. Infect.</source><year>2023</year><volume>29</volume><fpage>490</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2022.10.004</pub-id><pub-id pub-id-type="pmid">36216237</pub-id></element-citation></ref><ref id="B39-microorganisms-11-03004"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutob</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Justo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bookstaver</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Kohn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Albrecht</surname><given-names>H.</given-names></name><name name-style="western"><surname>Al-Hasan</surname><given-names>M.N.</given-names></name></person-group><article-title>Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections</article-title><source>Int. J. Antimicrob. Agents</source><year>2016</year><volume>48</volume><fpage>498</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2016.07.013</pub-id><pub-id pub-id-type="pmid">27590704</pub-id></element-citation></ref><ref id="B40-microorganisms-11-03004"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mogle</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Beccari</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Steele</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Fazili</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kufel</surname><given-names>W.D.</given-names></name></person-group><article-title>Clinical considerations for oral beta-lactams as step-down therapy for Enterobacteriaceae bloodstream infections</article-title><source>Expert. Opin. Pharmacother.</source><year>2019</year><volume>20</volume><fpage>903</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1080/14656566.2019.1594774</pub-id><pub-id pub-id-type="pmid">30908107</pub-id></element-citation></ref><ref id="B41-microorganisms-11-03004"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez-Gasc&#243;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aguirre-Qui&#241;onero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Canut-Blasco</surname><given-names>A.</given-names></name></person-group><article-title>Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective</article-title><source>Enferm. Infecc. Microbiol. Clin.</source><year>2020</year><volume>38</volume><fpage>306</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.eimc.2019.12.017</pub-id><pub-id pub-id-type="pmid">32085928</pub-id></element-citation></ref><ref id="B42-microorganisms-11-03004"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Minami</surname><given-names>K.</given-names></name><name name-style="western"><surname>Oda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishihara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uchiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ukimura</surname><given-names>A.</given-names></name></person-group><article-title>Probability of target attainment of oral antimicrobials for Escherichia coli and Klebsiella pneumoniae based on Monte Carlo simulations</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2022</year><volume>103</volume><elocation-id>115662</elocation-id><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2022.115662</pub-id><pub-id pub-id-type="pmid">35321800</pub-id></element-citation></ref><ref id="B43-microorganisms-11-03004"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Everts</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Gardiner</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Begg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Turnidge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Begg</surname><given-names>E.J.</given-names></name></person-group><article-title>Probenecid effects on cephalexin pharmacokinetics and pharmacodynamics in healthy volunteers</article-title><source>J. Infect.</source><year>2021</year><volume>83</volume><fpage>182</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2021.05.037</pub-id><pub-id pub-id-type="pmid">34081957</pub-id></element-citation></ref><ref id="B44-microorganisms-11-03004"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iversen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ihlemann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Elming</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Bruun</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>H&#248;fsten</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Fursted</surname><given-names>K.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>380</volume><fpage>415</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1808312</pub-id><pub-id pub-id-type="pmid">30152252</pub-id></element-citation></ref><ref id="B45-microorganisms-11-03004"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smit</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sen</surname><given-names>S.</given-names></name><name name-style="western"><surname>von Dach</surname><given-names>E.</given-names></name><name name-style="western"><surname>Karmime</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lescuyer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tonoli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bielicki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huttner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pfister</surname><given-names>M.</given-names></name></person-group><article-title>Steering Away from Current Amoxicillin Dose Reductions in Hospitalized Patients with Impaired Kidney Function to Avoid Subtherapeutic Drug Exposure</article-title><source>Antibiotics</source><year>2022</year><volume>11</volume><elocation-id>1190</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics11091190</pub-id><pub-id pub-id-type="pmid">36139969</pub-id><pub-id pub-id-type="pmcid">PMC9494977</pub-id></element-citation></ref><ref id="B46-microorganisms-11-03004"><label>46.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Gilbert</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Chamber</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Saag</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Pavia</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Black</surname><given-names>D.</given-names></name></person-group><source>The Sanford Guide to Antimicrobial Therapy</source><edition>53rd ed.</edition><publisher-name>Antimicrobial Therapy, Inc.</publisher-name><publisher-loc>Sperryville, VA, USA</publisher-loc><year>2023</year></element-citation></ref><ref id="B47-microorganisms-11-03004"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cattrall</surname><given-names>J.W.S.</given-names></name><name name-style="western"><surname>As&#237;n-Prieto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Troc&#243;niz</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>A.</given-names></name></person-group><article-title>A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2019</year><volume>38</volume><fpage>2311</fpage><lpage>2321</lpage><pub-id pub-id-type="doi">10.1007/s10096-019-03679-9</pub-id><pub-id pub-id-type="pmid">31494827</pub-id><pub-id pub-id-type="pmcid">PMC6858297</pub-id></element-citation></ref><ref id="B48-microorganisms-11-03004"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Velde</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Winter</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name></person-group><article-title>Non-linear absorption pharmacokinetics of amoxicillin: Consequences for dosing regimens and clinical breakpoints</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>2909</fpage><lpage>2917</lpage><pub-id pub-id-type="doi">10.1093/jac/dkw226</pub-id><pub-id pub-id-type="pmid">27330071</pub-id></element-citation></ref><ref id="B49-microorganisms-11-03004"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bathini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jandoc</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kuwornu</surname><given-names>P.</given-names></name><name name-style="western"><surname>McArthur</surname><given-names>E.</given-names></name><name name-style="western"><surname>Weir</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sood</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Battistella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Muanda</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A.K.</given-names></name><etal/></person-group><article-title>Clinical Outcomes of Failing to Dose-Reduce Cephalosporin Antibiotics in Older Adults with CKD</article-title><source>Clin. J. Am. Soc. Nephrol.</source><year>2019</year><volume>14</volume><fpage>197</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.2215/CJN.10710918</pub-id><pub-id pub-id-type="pmid">30630861</pub-id><pub-id pub-id-type="pmcid">PMC6390923</pub-id></element-citation></ref><ref id="B50-microorganisms-11-03004"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Fung</surname><given-names>C.P.</given-names></name></person-group><article-title>Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?</article-title><source>Infection</source><year>2018</year><volume>46</volume><fpage>365</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1007/s15010-018-1131-7</pub-id><pub-id pub-id-type="pmid">29556979</pub-id></element-citation></ref><ref id="B51-microorganisms-11-03004"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reid</surname><given-names>E.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Destache</surname><given-names>C.J.</given-names></name></person-group><article-title>Beta-Lactam vs. Fluoroquinolone Monotherapy for Pseudomonas aeruginosa Infection: A Systematic Review and Meta-Analysis</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>1483</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10121483</pub-id><pub-id pub-id-type="pmid">34943695</pub-id><pub-id pub-id-type="pmcid">PMC8698261</pub-id></element-citation></ref><ref id="B52-microorganisms-11-03004"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouza</surname><given-names>E.</given-names></name><name name-style="western"><surname>D&#237;az-L&#243;pez</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Bernaldo de Quir&#243;s</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Cr&#233;ixems</surname><given-names>M.</given-names></name></person-group><article-title>Ciprofloxacin in patients with bacteremic infections. The Spanish Group for the Study of Ciprofloxacin</article-title><source>Am. J. Med.</source><year>1989</year><volume>87</volume><fpage>228s</fpage><lpage>231s</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(89)90065-X</pub-id><pub-id pub-id-type="pmid">2589366</pub-id></element-citation></ref><ref id="B53-microorganisms-11-03004"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pradubkham</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suwanpimolkul</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Nakaranurack</surname><given-names>C.</given-names></name></person-group><article-title>Intravenous to oral transition of antibiotics for gram-negative bloodstream infection at a University hospital in Thailand: Clinical outcomes and predictors of treatment failure</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0273369</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0273369</pub-id><pub-id pub-id-type="pmid">36137077</pub-id><pub-id pub-id-type="pmcid">PMC9499306</pub-id></element-citation></ref><ref id="B54-microorganisms-11-03004"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forrest</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nix</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Ballow</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Goss</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Birmingham</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Schentag</surname><given-names>J.J.</given-names></name></person-group><article-title>Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients</article-title><source>Antimicrob. Agents Chemother.</source><year>1993</year><volume>37</volume><fpage>1073</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.5.1073</pub-id><pub-id pub-id-type="pmid">8517694</pub-id><pub-id pub-id-type="pmcid">PMC187901</pub-id></element-citation></ref><ref id="B55-microorganisms-11-03004"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Zanten</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Polderman</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>van Geijlswijk</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Schouten</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Girbes</surname><given-names>A.R.</given-names></name></person-group><article-title>Ciprofloxacin pharmacokinetics in critically ill patients: A prospective cohort study</article-title><source>J. Crit. Care</source><year>2008</year><volume>23</volume><fpage>422</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2007.11.011</pub-id><pub-id pub-id-type="pmid">18725050</pub-id></element-citation></ref><ref id="B56-microorganisms-11-03004"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vroom</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>van Hest</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>van Daalen</surname><given-names>F.V.</given-names></name><name name-style="western"><surname>Kuil</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Math&#244;t</surname><given-names>R.A.A.</given-names></name><name name-style="western"><surname>Geerlings</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Jager</surname><given-names>N.G.L.</given-names></name></person-group><article-title>Pharmacokinetic/pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><volume>56</volume><fpage>106166</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106166</pub-id><pub-id pub-id-type="pmid">32941947</pub-id></element-citation></ref><ref id="B57-microorganisms-11-03004"><label>57.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><article-title>Ciprofloxacin Bayer Referral Annex</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/referral/ciprofloxacin-bayer-article-30-referral-annex-i-ii-iii_en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-11-11">(accessed on 11 November 2023)</date-in-citation></element-citation></ref><ref id="B58-microorganisms-11-03004"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohwedder</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bergan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thorsteinsson</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Scholl</surname><given-names>H.</given-names></name></person-group><article-title>Transintestinal elimination of ciprofloxacin</article-title><source>Chemotherapy</source><year>1990</year><volume>36</volume><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1159/000238751</pub-id><pub-id pub-id-type="pmid">2311444</pub-id></element-citation></ref><ref id="B59-microorganisms-11-03004"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carney</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Fossieck</surname><given-names>B.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Staphylococcal bacteremia in cancer patients: Intravenous and oral antimicrobial therapy</article-title><source>South. Med. J.</source><year>1982</year><volume>75</volume><fpage>143</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1097/00007611-198202000-00006</pub-id><pub-id pub-id-type="pmid">7036355</pub-id></element-citation></ref><ref id="B60-microorganisms-11-03004"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diego-Yag&#252;e</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mora-Vargas</surname><given-names>A.</given-names></name><name name-style="western"><surname>V&#225;zquez-Comendador</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Santamarina-Alcantud</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Cruz</surname><given-names>A.</given-names></name><name name-style="western"><surname>M&#250;&#241;ez-Rubio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guti&#233;rrez-Villanueva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sanchez-Romero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Moreno-Torres</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ramos-Mart&#237;nez</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Sequential oral antibiotic in uncomplicated Staphylococcus aureus bacteraemia: A propensity-matched cohort analysis</article-title><source>Clin. Microbiol. Infect.</source><year>2023</year><volume>29</volume><fpage>744</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2023.02.001</pub-id><pub-id pub-id-type="pmid">36773773</pub-id></element-citation></ref><ref id="B61-microorganisms-11-03004"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bupha-Intr</surname><given-names>O.</given-names></name><name name-style="western"><surname>Blackmore</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bloomfield</surname><given-names>M.</given-names></name></person-group><article-title>Efficacy of Early Oral Switch with &#946;-Lactams for Low-Risk Staphylococcus aureus Bacteremia</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e02345-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.02345-19</pub-id><pub-id pub-id-type="pmid">32015029</pub-id><pub-id pub-id-type="pmcid">PMC7318028</pub-id></element-citation></ref><ref id="B62-microorganisms-11-03004"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jorgensen</surname><given-names>S.C.J.</given-names></name><name name-style="western"><surname>Lagnf</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shamim</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Rybak</surname><given-names>M.J.</given-names></name></person-group><article-title>Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: One step closer</article-title><source>J. Antimicrob. Chemother.</source><year>2019</year><volume>74</volume><fpage>489</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1093/jac/dky452</pub-id><pub-id pub-id-type="pmid">30418557</pub-id></element-citation></ref><ref id="B63-microorganisms-11-03004"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;rez-Rodr&#237;guez</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moreno-Flores</surname><given-names>A.</given-names></name><name name-style="western"><surname>Longueira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Di&#233;guez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Su&#225;rez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vasallo</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>&#193;lvarez-Fern&#225;ndez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>M.</given-names></name></person-group><article-title>The benefits and safety of oral sequential antibiotic therapy in non-complicated and complicated Staphylococcus aureus bacteremia</article-title><source>Int. J. Infect. Dis.</source><year>2021</year><volume>102</volume><fpage>554</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.10.097</pub-id><pub-id pub-id-type="pmid">33157291</pub-id></element-citation></ref><ref id="B64-microorganisms-11-03004"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Rombach</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zambellas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>McNally</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Lipsky</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Bose</surname><given-names>D.</given-names></name><name name-style="western"><surname>K&#252;min</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Oral versus Intravenous Antibiotics for Bone and Joint Infection</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>380</volume><fpage>425</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1710926</pub-id><pub-id pub-id-type="pmid">30699315</pub-id><pub-id pub-id-type="pmcid">PMC6522347</pub-id></element-citation></ref><ref id="B65-microorganisms-11-03004"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wildenthal</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Atkinson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sayood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Marschall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Durkin</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>L.R.</given-names></name></person-group><article-title>Outcomes of Partial Oral Antibiotic Treatment for Complicated Staphylococcus aureus Bacteremia in People Who Inject Drugs</article-title><source>Clin. Infect. Dis.</source><year>2023</year><volume>76</volume><fpage>487</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac714</pub-id><pub-id pub-id-type="pmid">36052413</pub-id><pub-id pub-id-type="pmcid">PMC10169408</pub-id></element-citation></ref><ref id="B66-microorganisms-11-03004"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shorr</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Kunkel</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kollef</surname><given-names>M.</given-names></name></person-group><article-title>Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: Pooled analysis of randomized studies</article-title><source>J. Antimicrob. Chemother.</source><year>2005</year><volume>56</volume><fpage>923</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1093/jac/dki355</pub-id><pub-id pub-id-type="pmid">16195255</pub-id></element-citation></ref><ref id="B67-microorganisms-11-03004"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schrenzel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harbarth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schockmel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Genn&#233;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bregenzer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Flueckiger</surname><given-names>U.</given-names></name><name name-style="western"><surname>Petignat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>F.</given-names></name><name name-style="western"><surname>Francioli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zimmerli</surname><given-names>W.</given-names></name><etal/></person-group><article-title>A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection</article-title><source>Clin. Infect. Dis.</source><year>2004</year><volume>39</volume><fpage>1285</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1086/424506</pub-id><pub-id pub-id-type="pmid">15494904</pub-id></element-citation></ref><ref id="B68-microorganisms-11-03004"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Horner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E.M.</given-names></name></person-group><article-title>Treatment of methicillin-resistant Staphylococcus aureus (MRSA): Updated guidelines from the UK</article-title><source>JAC Antimicrob. Resist.</source><year>2021</year><volume>3</volume><fpage>dlaa114</fpage><pub-id pub-id-type="doi">10.1093/jacamr/dlaa114</pub-id><pub-id pub-id-type="pmid">34223066</pub-id><pub-id pub-id-type="pmcid">PMC8210269</pub-id></element-citation></ref><ref id="B69-microorganisms-11-03004"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bishara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yahav</surname><given-names>D.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Neuberger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghanem-Zoubi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dickstein</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nseir</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leibovici</surname><given-names>L.</given-names></name></person-group><article-title>Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: Randomised controlled trial</article-title><source>BMJ</source><year>2015</year><volume>350</volume><fpage>h2219</fpage><pub-id pub-id-type="doi">10.1136/bmj.h2219</pub-id><pub-id pub-id-type="pmid">25977146</pub-id><pub-id pub-id-type="pmcid">PMC4431679</pub-id></element-citation></ref><ref id="B70-microorganisms-11-03004"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaasch</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>L&#243;pez-Cort&#233;s</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Ba&#241;o</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cisneros</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>F&#228;tkenheuer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rieg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lepeule</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coutte</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Early oral switch in low-risk <italic toggle="yes">Staphylococcus aureus</italic> bloodstream infection</article-title><source>medRxiv</source><year>2023</year><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1101/2023.07.03.23291932</pub-id></element-citation></ref><ref id="B71-microorganisms-11-03004"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: Analysis of a prospective observational cohort study</article-title><source>Antimicrob. Agents Chemother.</source><year>2013</year><volume>57</volume><fpage>1150</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1128/AAC.01021-12</pub-id><pub-id pub-id-type="pmid">23254436</pub-id><pub-id pub-id-type="pmcid">PMC3591920</pub-id></element-citation></ref><ref id="B72-microorganisms-11-03004"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crowley</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>D.K.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Rimmer</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Todd</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cabell</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Reller</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>V.G.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremia</article-title><source>Crit. Care Med.</source><year>2008</year><volume>36</volume><fpage>385</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0B013E3181611F914</pub-id><pub-id pub-id-type="pmid">18091541</pub-id></element-citation></ref><ref id="B73-microorganisms-11-03004"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilcox</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Tack</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Bouza</surname><given-names>E.</given-names></name><name name-style="western"><surname>Herr</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Ruf</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Ijzerman</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Croos-Dabrera</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Kunkel</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Knirsch</surname><given-names>C.</given-names></name></person-group><article-title>Complicated skin and skin-structure infections and catheter-related bloodstream infections: Noninferiority of linezolid in a phase 3 study</article-title><source>Clin. Infect. Dis.</source><year>2009</year><volume>48</volume><fpage>203</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1086/595686</pub-id><pub-id pub-id-type="pmid">19072714</pub-id></element-citation></ref><ref id="B74-microorganisms-11-03004"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeager</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Shorman</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Veve</surname><given-names>M.P.</given-names></name></person-group><article-title>Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections</article-title><source>Int. J. Antimicrob. Agents</source><year>2021</year><volume>57</volume><fpage>106329</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2021.106329</pub-id><pub-id pub-id-type="pmid">33785363</pub-id></element-citation></ref><ref id="B75-microorganisms-11-03004"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willekens</surname><given-names>R.</given-names></name><name name-style="western"><surname>Puig-Asensio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruiz-Camps</surname><given-names>I.</given-names></name><name name-style="western"><surname>Larrosa</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-L&#243;pez</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Pardo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Hidalgo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pigrau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Almirante</surname><given-names>B.</given-names></name></person-group><article-title>Early Oral Switch to Linezolid for Low-risk Patients With Staphylococcus aureus Bloodstream Infections: A Propensity-matched Cohort Study</article-title><source>Clin. Infect. Dis.</source><year>2019</year><volume>69</volume><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy916</pub-id><pub-id pub-id-type="pmid">30351401</pub-id></element-citation></ref><ref id="B76-microorganisms-11-03004"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guthridge</surname><given-names>I.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.</given-names></name><name name-style="western"><surname>Law</surname><given-names>M.</given-names></name><name name-style="western"><surname>Binotto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>J.</given-names></name></person-group><article-title>Efficacy and Safety of Intravenous Lincosamide Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia</article-title><source>Antimicrob. Agents Chemother.</source><year>2021</year><volume>65</volume><fpage>e0034321</fpage><pub-id pub-id-type="doi">10.1128/AAC.00343-21</pub-id><pub-id pub-id-type="pmid">34125589</pub-id><pub-id pub-id-type="pmcid">PMC8370195</pub-id></element-citation></ref><ref id="B77-microorganisms-11-03004"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouazza</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pestre</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jullien</surname><given-names>V.</given-names></name><name name-style="western"><surname>Curis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Urien</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tr&#233;luyer</surname><given-names>J.M.</given-names></name></person-group><article-title>Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis</article-title><source>Br. J. Clin. Pharmacol.</source><year>2012</year><volume>74</volume><fpage>971</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2012.04292.x</pub-id><pub-id pub-id-type="pmid">22486719</pub-id><pub-id pub-id-type="pmcid">PMC3522810</pub-id></element-citation></ref><ref id="B78-microorganisms-11-03004"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duckworth</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Cogburn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nesbit</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Wray</surname><given-names>C.H.</given-names></name></person-group><article-title>Tissue penetration of clindamycin in diabetic foot infections</article-title><source>J. Antimicrob. Chemother.</source><year>1993</year><volume>31</volume><fpage>581</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1093/jac/31.4.581</pub-id><pub-id pub-id-type="pmid">8514652</pub-id></element-citation></ref><ref id="B79-microorganisms-11-03004"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kermarrec</surname><given-names>G.</given-names></name><name name-style="western"><surname>Parize</surname><given-names>P.</given-names></name><name name-style="western"><surname>Caruba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bouvet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mainardi</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Sabatier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nich</surname><given-names>C.</given-names></name></person-group><article-title>Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination</article-title><source>J. Infect.</source><year>2015</year><volume>71</volume><fpage>200</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2015.03.013</pub-id><pub-id pub-id-type="pmid">25936632</pub-id></element-citation></ref><ref id="B80-microorganisms-11-03004"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeller</surname><given-names>V.</given-names></name><name name-style="western"><surname>Magreault</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heym</surname><given-names>B.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kitzis</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Billaud</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marmor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jannot</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Salomon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jullien</surname><given-names>V.</given-names></name></person-group><article-title>Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: A prospective pharmacokinetic study</article-title><source>Clin. Microbiol. Infect.</source><year>2021</year><volume>27</volume><fpage>1857.e1851</fpage><lpage>1857.e1857</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2021.04.017</pub-id><pub-id pub-id-type="pmid">33915288</pub-id></element-citation></ref><ref id="B81-microorganisms-11-03004"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vostrov</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Kononenko</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Lubenko</surname><given-names>I.Y.</given-names></name><name name-style="western"><surname>Zinner</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Firsov</surname><given-names>A.A.</given-names></name></person-group><article-title>Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: Prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio</article-title><source>Antimicrob. Agents Chemother.</source><year>2000</year><volume>44</volume><fpage>879</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1128/AAC.44.4.879-884.2000</pub-id><pub-id pub-id-type="pmid">10722485</pub-id><pub-id pub-id-type="pmcid">PMC89786</pub-id></element-citation></ref><ref id="B82-microorganisms-11-03004"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Firsov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Lubenko</surname><given-names>I.Y.</given-names></name><name name-style="western"><surname>Vostrov</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Kononenko</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Zinner</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Portnoy</surname><given-names>Y.A.</given-names></name></person-group><article-title>Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: Prediction of the equivalent AUC/MIC breakpoints and equiefficient doses</article-title><source>J. Antimicrob. Chemother.</source><year>2000</year><volume>46</volume><fpage>725</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1093/jac/46.5.725</pub-id><pub-id pub-id-type="pmid">11062191</pub-id></element-citation></ref><ref id="B83-microorganisms-11-03004"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iqbal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Broeker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rahmel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nussbaumer-Pr&#246;ll</surname><given-names>A.</given-names></name><name name-style="western"><surname>&#214;sterreicher</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zeitlinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>S.G.</given-names></name></person-group><article-title>A pharmacometric approach to define target site-specific breakpoints for bacterial killing and resistance suppression integrating microdialysis, time-kill curves and heteroresistance data: A case study with moxifloxacin</article-title><source>Clin. Microbiol. Infect.</source><year>2020</year><volume>26</volume><fpage>1255.e1251</fpage><lpage>1255.e1258</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.02.013</pub-id><pub-id pub-id-type="pmid">32088331</pub-id></element-citation></ref><ref id="B84-microorganisms-11-03004"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruslami</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ganiem</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Dian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Apriani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Achmad</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>van der Ven</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Borm</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aarnoutse</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name></person-group><article-title>Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: An open-label, randomised controlled phase 2 trial</article-title><source>Lancet Infect. Dis.</source><year>2013</year><volume>13</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(12)70264-5</pub-id><pub-id pub-id-type="pmid">23103177</pub-id></element-citation></ref><ref id="B85-microorganisms-11-03004"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>San Juan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garcia-Reyne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caba</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chaves</surname><given-names>F.</given-names></name><name name-style="western"><surname>Resines</surname><given-names>C.</given-names></name><name name-style="western"><surname>Llanos</surname><given-names>F.</given-names></name><name name-style="western"><surname>L&#243;pez-Medrano</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lizasoain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aguado</surname><given-names>J.M.</given-names></name></person-group><article-title>Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections</article-title><source>Antimicrob. Agents Chemother.</source><year>2010</year><volume>54</volume><fpage>5161</fpage><lpage>5166</lpage><pub-id pub-id-type="doi">10.1128/AAC.00027-10</pub-id><pub-id pub-id-type="pmid">20855727</pub-id><pub-id pub-id-type="pmcid">PMC2981285</pub-id></element-citation></ref><ref id="B86-microorganisms-11-03004"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wouthuyzen-Bakker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tornero</surname><given-names>E.</given-names></name><name name-style="western"><surname>Morata</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nannan Panday</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Jutte</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Bori</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kampinga</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Soriano</surname><given-names>A.</given-names></name></person-group><article-title>Moxifloxacin plus rifampin as an alternative for levofloxacin plus rifampin in the treatment of a prosthetic joint infection with Staphylococcus aureus</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>51</volume><fpage>38</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.04.011</pub-id><pub-id pub-id-type="pmid">28668678</pub-id></element-citation></ref><ref id="B87-microorganisms-11-03004"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nijland</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Ruslami</surname><given-names>R.</given-names></name><name name-style="western"><surname>Suroto</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Burger</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Alisjahbana</surname><given-names>B.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aarnoutse</surname><given-names>R.E.</given-names></name></person-group><article-title>Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis</article-title><source>Clin. Infect. Dis.</source><year>2007</year><volume>45</volume><fpage>1001</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1086/521894</pub-id><pub-id pub-id-type="pmid">17879915</pub-id></element-citation></ref><ref id="B88-microorganisms-11-03004"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramachandran</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hemanth Kumar</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Geetharani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sugirda</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nandhakumar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nandini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tharani</surname><given-names>C.B.</given-names></name></person-group><article-title>Effect of rifampicin &amp; isoniazid on the steady state pharmacokinetics of moxifloxacin</article-title><source>Indian J. Med. Res.</source><year>2012</year><volume>136</volume><fpage>979</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">23391793</pub-id><pub-id pub-id-type="pmcid">PMC3612327</pub-id></element-citation></ref><ref id="B89-microorganisms-11-03004"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmerli</surname><given-names>W.</given-names></name><name name-style="western"><surname>Widmer</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Blatter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Frei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ochsner</surname><given-names>P.E.</given-names></name></person-group><article-title>Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group</article-title><source>JAMA</source><year>1998</year><volume>279</volume><fpage>1537</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1001/jama.279.19.1537</pub-id><pub-id pub-id-type="pmid">9605897</pub-id></element-citation></ref><ref id="B90-microorganisms-11-03004"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rieg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joost</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wei&#223;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Peyerl-Hoffmann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hellmich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kern</surname><given-names>W.V.</given-names></name><name name-style="western"><surname>Kaasch</surname><given-names>A.</given-names></name></person-group><article-title>Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia-a post hoc analysis in 964 prospectively evaluated patients</article-title><source>Clin. Microbiol. Infect.</source><year>2017</year><volume>23</volume><fpage>406.e401</fpage><lpage>406.e408</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2016.08.026</pub-id><pub-id pub-id-type="pmid">27615722</pub-id></element-citation></ref><ref id="B91-microorganisms-11-03004"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rieg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peyerl-Hoffmann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Joost</surname><given-names>I.</given-names></name><name name-style="western"><surname>Camp</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hellmich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kern</surname><given-names>W.V.</given-names></name><name name-style="western"><surname>Kaasch</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>H.</given-names></name></person-group><article-title>Combination therapy with rifampicin or fosfomycin in patients with Staphylococcus aureus bloodstream infection at high risk for complications or relapse: Results of a large prospective observational cohort</article-title><source>J. Antimicrob. Chemother.</source><year>2020</year><volume>75</volume><fpage>2282</fpage><lpage>2290</lpage><pub-id pub-id-type="doi">10.1093/jac/dkaa144</pub-id><pub-id pub-id-type="pmid">32355950</pub-id></element-citation></ref><ref id="B92-microorganisms-11-03004"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldstein</surname><given-names>E.J.C.</given-names></name><name name-style="western"><surname>Citron</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Warren</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Tyrrell</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Rybak</surname><given-names>M.J.</given-names></name></person-group><article-title>Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus</article-title><source>J. Med. Microbiol.</source><year>2008</year><volume>57</volume><fpage>452</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.47580-0</pub-id><pub-id pub-id-type="pmid">18349364</pub-id></element-citation></ref><ref id="B93-microorganisms-11-03004"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramirez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bordon</surname><given-names>J.</given-names></name></person-group><article-title>Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia</article-title><source>Arch. Intern. Med.</source><year>2001</year><volume>161</volume><fpage>848</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1001/archinte.161.6.848</pub-id><pub-id pub-id-type="pmid">11268227</pub-id></element-citation></ref><ref id="B94-microorganisms-11-03004"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siquier</surname><given-names>B.</given-names></name><name name-style="western"><surname>S&#225;nchez-Alvarez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garc&#237;a-Mendez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sabri&#225;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pallar&#233;s</surname><given-names>R.</given-names></name><name name-style="western"><surname>Twynholm</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dal-R&#233;</surname><given-names>R.</given-names></name></person-group><article-title>Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae</article-title><source>J. Antimicrob. Chemother.</source><year>2006</year><volume>57</volume><fpage>536</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1093/jac/dki480</pub-id><pub-id pub-id-type="pmid">16446376</pub-id></element-citation></ref><ref id="B95-microorganisms-11-03004"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beuttler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Minejima</surname><given-names>E.</given-names></name></person-group><article-title>Evaluation of step-down oral antibiotic therapy for uncomplicated streptococcal bloodstream infections on clinical outcomes</article-title><source>Ther. Adv. Infect. Dis.</source><year>2022</year><volume>9</volume><fpage>20499361211073248</fpage><pub-id pub-id-type="doi">10.1177/20499361211073248</pub-id><pub-id pub-id-type="pmid">35127081</pub-id><pub-id pub-id-type="pmcid">PMC8808041</pub-id></element-citation></ref><ref id="B96-microorganisms-11-03004"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waked</surname><given-names>R.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Mercuro</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Wungwattana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rokas</surname><given-names>K.E.</given-names></name></person-group><article-title>Uncomplicated Streptococcal Bacteremia: The Era of Oral Antibiotic Step-down Therapy?</article-title><source>Int. J. Antimicrob. Agents</source><year>2023</year><volume>61</volume><fpage>106736</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2023.106736</pub-id><pub-id pub-id-type="pmid">36690120</pub-id><pub-id pub-id-type="pmcid">PMC10023366</pub-id></element-citation></ref><ref id="B97-microorganisms-11-03004"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broermann</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Al-Hasan</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Withers</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benbow</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Ramsey</surname><given-names>T.</given-names></name><name name-style="western"><surname>McTavish</surname><given-names>M.</given-names></name><name name-style="western"><surname>Winders</surname><given-names>H.R.</given-names></name></person-group><article-title>Intravenous versus Partial Oral Antibiotic Therapy in the Treatment of Uncomplicated Bloodstream Infection Due to Streptococcus Species</article-title><source>Microorganisms</source><year>2023</year><volume>11</volume><elocation-id>2313</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms11092313</pub-id><pub-id pub-id-type="pmid">37764157</pub-id><pub-id pub-id-type="pmcid">PMC10536542</pub-id></element-citation></ref><ref id="B98-microorganisms-11-03004"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos-Otero</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Sarangarm</surname><given-names>P.</given-names></name><name name-style="western"><surname>Walraven</surname><given-names>C.</given-names></name></person-group><article-title>A Retrospective Analysis of Intravenous vs Oral Antibiotic Step-Down Therapy for the Treatment of Uncomplicated Streptococcal Bloodstream Infections</article-title><source>J. Clin. Pharmacol.</source><year>2022</year><volume>62</volume><fpage>1372</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1002/jcph.2097</pub-id><pub-id pub-id-type="pmid">35661173</pub-id></element-citation></ref><ref id="B99-microorganisms-11-03004"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arensman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shields</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beganovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>LaChance</surname><given-names>E.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dela-Pena</surname><given-names>J.</given-names></name></person-group><article-title>Fluoroquinolone versus Beta-Lactam Oral Step-Down Therapy for Uncomplicated Streptococcal Bloodstream Infections</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e01515-20</fpage><pub-id pub-id-type="doi">10.1128/AAC.01515-20</pub-id><pub-id pub-id-type="pmid">32839223</pub-id><pub-id pub-id-type="pmcid">PMC7577143</pub-id></element-citation></ref><ref id="B100-microorganisms-11-03004"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yetmar</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Chesdachai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lahr</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Challener</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Arensman Hannan</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Epps</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Seville</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Tande</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Virk</surname><given-names>A.</given-names></name></person-group><article-title>Comparison of Oral and Intravenous Definitive Antibiotic Therapy for Beta-Hemolytic Streptococcus Species Bloodstream Infections from Soft Tissue Sources: A Propensity Score-Matched Analysis</article-title><source>Antimicrob. Agents Chemother.</source><year>2023</year><volume>67</volume><fpage>e0012023</fpage><pub-id pub-id-type="doi">10.1128/aac.00120-23</pub-id><pub-id pub-id-type="pmid">37191533</pub-id><pub-id pub-id-type="pmcid">PMC10269088</pub-id></element-citation></ref><ref id="B101-microorganisms-11-03004"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chater</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maley</surname><given-names>M.</given-names></name><name name-style="western"><surname>van Hal</surname><given-names>S.J.</given-names></name></person-group><article-title>Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteraemia</article-title><source>J. Antimicrob. Chemother.</source><year>2014</year><volume>69</volume><fpage>2252</fpage><lpage>2257</lpage><pub-id pub-id-type="doi">10.1093/jac/dku107</pub-id><pub-id pub-id-type="pmid">24744303</pub-id></element-citation></ref><ref id="B102-microorganisms-11-03004"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hemapanpairoa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Changpradub</surname><given-names>D.</given-names></name><name name-style="western"><surname>Santimaleeworagun</surname><given-names>W.</given-names></name></person-group><article-title>Clinical Impact of Vancomycin Treatment in Ampicillin-Susceptible Enterococci Bloodstream Infections</article-title><source>Antibiotics</source><year>2022</year><volume>11</volume><elocation-id>1698</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics11121698</pub-id><pub-id pub-id-type="pmid">36551355</pub-id><pub-id pub-id-type="pmcid">PMC9774542</pub-id></element-citation></ref><ref id="B103-microorganisms-11-03004"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rybak</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Le</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lodise</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Pai</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Wong-Beringer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rotschafer</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists</article-title><source>Am. J. Health Syst. Pharm.</source><year>2020</year><volume>77</volume><fpage>835</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1093/ajhp/zxaa036</pub-id><pub-id pub-id-type="pmid">32191793</pub-id></element-citation></ref><ref id="B104-microorganisms-11-03004"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Echeverria-Esnal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sorli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Prim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Conde-Est&#233;vez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mateu-De Antonio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martin-Ontiyuelo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Horcajada</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Grau</surname><given-names>S.</given-names></name></person-group><article-title>Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: A propensity score matched comparative study</article-title><source>Int. J. Antimicrob. Agents</source><year>2019</year><volume>54</volume><fpage>572</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2019.08.018</pub-id><pub-id pub-id-type="pmid">31476435</pub-id></element-citation></ref><ref id="B105-microorganisms-11-03004"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Britt</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Steed</surname><given-names>M.E.</given-names></name></person-group><article-title>Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia</article-title><source>Antimicrob. Agents Chemother.</source><year>2017</year><volume>61</volume><fpage>e02216-16</fpage><pub-id pub-id-type="doi">10.1128/AAC.02216-16</pub-id><pub-id pub-id-type="pmid">28264856</pub-id><pub-id pub-id-type="pmcid">PMC5404546</pub-id></element-citation></ref><ref id="B106-microorganisms-11-03004"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turnidge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kahlmeter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cant&#243;n</surname><given-names>R.</given-names></name><name name-style="western"><surname>MacGowan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giske</surname><given-names>C.G.</given-names></name></person-group><article-title>Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: A EUCAST position paper</article-title><source>Clin. Microbiol. Infect.</source><year>2020</year><volume>26</volume><fpage>1039</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.04.027</pub-id><pub-id pub-id-type="pmid">32353412</pub-id></element-citation></ref><ref id="B107-microorganisms-11-03004"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avery</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Kuti</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Weisser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Egli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rybak</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Zasowski</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Arias</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia</article-title><source>Int. J. Antimicrob. Agents</source><year>2019</year><volume>54</volume><fpage>346</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2019.07.002</pub-id><pub-id pub-id-type="pmid">31284042</pub-id></element-citation></ref><ref id="B108-microorganisms-11-03004"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>N.</given-names></name></person-group><article-title>Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: An updated systematic review and meta-analysis</article-title><source>J. Glob. Antimicrob. Resist.</source><year>2020</year><volume>21</volume><fpage>235</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2019.10.008</pub-id><pub-id pub-id-type="pmid">31629937</pub-id></element-citation></ref><ref id="B109-microorganisms-11-03004"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brier</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Stalker</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Aronoff</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Batts</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>O&#8217;Grady</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Jungbluth</surname><given-names>G.L.</given-names></name></person-group><article-title>Pharmacokinetics of linezolid in subjects with renal dysfunction</article-title><source>Antimicrob. Agents Chemother.</source><year>2003</year><volume>47</volume><fpage>2775</fpage><lpage>2780</lpage><pub-id pub-id-type="doi">10.1128/AAC.47.9.2775-2780.2003</pub-id><pub-id pub-id-type="pmid">12936973</pub-id><pub-id pub-id-type="pmcid">PMC182634</pub-id></element-citation></ref><ref id="B110-microorganisms-11-03004"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slatter</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Stalker</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Feenstra</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Welshman</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Bruss</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Sams</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Hauer</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Fagerness</surname><given-names>P.E.</given-names></name><etal/></person-group><article-title>Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects</article-title><source>Drug. Metab. Dispos.</source><year>2001</year><volume>29</volume><fpage>1136</fpage><lpage>1145</lpage><pub-id pub-id-type="pmid">11454733</pub-id></element-citation></ref><ref id="B111-microorganisms-11-03004"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdul-Aziz</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Bassetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bracht</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dimopoulos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>D.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sjovall</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper</article-title><source>Intensive Care Med.</source><year>2020</year><volume>46</volume><fpage>1127</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.1007/s00134-020-06050-1</pub-id><pub-id pub-id-type="pmid">32383061</pub-id><pub-id pub-id-type="pmcid">PMC7223855</pub-id></element-citation></ref><ref id="B112-microorganisms-11-03004"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Expert consensus statement on therapeutic drug monitoring and individualization of linezolid</article-title><source>Front. Public Health</source><year>2022</year><volume>10</volume><fpage>967311</fpage><pub-id pub-id-type="doi">10.3389/fpubh.2022.967311</pub-id><pub-id pub-id-type="pmid">36033811</pub-id><pub-id pub-id-type="pmcid">PMC9399604</pub-id></element-citation></ref><ref id="B113-microorganisms-11-03004"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Osa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saiki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nagai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Enoki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Taguchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>K.</given-names></name></person-group><article-title>Safety of linezolid in patients with decreased renal function and trough monitoring: A systematic review and meta-analysis</article-title><source>BMC Pharmacol. Toxicol.</source><year>2022</year><volume>23</volume><elocation-id>89</elocation-id><pub-id pub-id-type="doi">10.1186/s40360-022-00628-9</pub-id><pub-id pub-id-type="pmid">36451204</pub-id><pub-id pub-id-type="pmcid">PMC9714190</pub-id></element-citation></ref><ref id="B114-microorganisms-11-03004"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta-analysis</article-title><source>Br. J. Clin. Pharmacol.</source><year>2022</year><volume>88</volume><fpage>464</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1111/bcp.14965</pub-id><pub-id pub-id-type="pmid">34192814</pub-id><pub-id pub-id-type="pmcid">PMC9292275</pub-id></element-citation></ref><ref id="B115-microorganisms-11-03004"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matsuo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Higashi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hirayama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kosugi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nishizawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshio</surname><given-names>T.</given-names></name></person-group><article-title>A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia</article-title><source>J. Infect. Chemother.</source><year>2016</year><volume>22</volume><fpage>536</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2016.05.003</pub-id><pub-id pub-id-type="pmid">27321773</pub-id></element-citation></ref><ref id="B116-microorganisms-11-03004"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crass</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Cojutti</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Pai</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F.</given-names></name></person-group><article-title>Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety</article-title><source>Antimicrob. Agents Chemother.</source><year>2019</year><volume>63</volume><fpage>e00605-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.00605-19</pub-id><pub-id pub-id-type="pmid">31109977</pub-id><pub-id pub-id-type="pmcid">PMC6658752</pub-id></element-citation></ref><ref id="B117-microorganisms-11-03004"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Population Pharmacokinetics and Dosage Optimization of Linezolid in Patients with Liver Dysfunction</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>eaac.00133-20</fpage><pub-id pub-id-type="doi">10.1128/AAC.00133-20</pub-id><pub-id pub-id-type="pmcid">PMC7269467</pub-id><pub-id pub-id-type="pmid">32253210</pub-id></element-citation></ref><ref id="B118-microorganisms-11-03004"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soraluce</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barrasa</surname><given-names>H.</given-names></name><name name-style="western"><surname>As&#237;n-Prieto</surname><given-names>E.</given-names></name><name name-style="western"><surname>S&#225;nchez-Izquierdo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maynar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Isla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gasc&#243;n</surname><given-names>A.</given-names></name></person-group><article-title>Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>54</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12010054</pub-id><pub-id pub-id-type="pmid">31936614</pub-id><pub-id pub-id-type="pmcid">PMC7023070</pub-id></element-citation></ref><ref id="B119-microorganisms-11-03004"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ehmann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Busse</surname><given-names>D.</given-names></name><name name-style="western"><surname>Petroff</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dorn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huisinga</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zeitlinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wrigge</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>C.</given-names></name></person-group><article-title>Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy</article-title><source>Clin. Microbiol. Infect.</source><year>2020</year><volume>26</volume><fpage>1222</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.04.009</pub-id><pub-id pub-id-type="pmid">32311473</pub-id></element-citation></ref><ref id="B120-microorganisms-11-03004"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blackman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Jarugula</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nicolau</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Chui</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heil</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Gopalakrishnan</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections</article-title><source>Antimicrob. Agents Chemother.</source><year>2021</year><volume>65</volume><fpage>e01619-20</fpage><pub-id pub-id-type="doi">10.1128/AAC.01619-20</pub-id><pub-id pub-id-type="pmid">33257446</pub-id><pub-id pub-id-type="pmcid">PMC7848975</pub-id></element-citation></ref><ref id="B121-microorganisms-11-03004"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Rhee</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wasmann</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>van der Linden</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Wiezer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Van Dongen</surname><given-names>E.P.A.</given-names></name><name name-style="western"><surname>Krekels</surname><given-names>E.H.J.</given-names></name><name name-style="western"><surname>Br&#252;ggemann</surname><given-names>R.J.M.</given-names></name><name name-style="western"><surname>Knibbe</surname><given-names>C.A.J.</given-names></name></person-group><article-title>Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study</article-title><source>Clin. Pharmacokinet.</source><year>2022</year><volume>61</volume><fpage>1167</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1007/s40262-022-01130-5</pub-id><pub-id pub-id-type="pmid">35641862</pub-id><pub-id pub-id-type="pmcid">PMC9349153</pub-id></element-citation></ref><ref id="B122-microorganisms-11-03004"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pai</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Cojutti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F.</given-names></name></person-group><article-title>Levofloxacin dosing regimen in severely morbidly obese patients (BMI &#8805; 40 kg/m<sup>2</sup>) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring</article-title><source>Clin. Pharmacokinet.</source><year>2014</year><volume>53</volume><fpage>753</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1007/s40262-014-0154-1</pub-id><pub-id pub-id-type="pmid">24989061</pub-id></element-citation></ref><ref id="B123-microorganisms-11-03004"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cook</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Morehead</surname><given-names>R.S.</given-names></name></person-group><article-title>Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults</article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>3240</fpage><lpage>3243</lpage><pub-id pub-id-type="doi">10.1128/AAC.01680-10</pub-id><pub-id pub-id-type="pmid">21576432</pub-id><pub-id pub-id-type="pmcid">PMC3122410</pub-id></element-citation></ref><ref id="B124-microorganisms-11-03004"><label>124.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>EUCAST</collab></person-group><article-title>EUCAST Clinical Breakpoints for Bacteria (v 13.1)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.eucast.org/clinical_breakpoints" ext-link-type="uri">https://www.eucast.org/clinical_breakpoints</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-11-11">(accessed on 11 November 2023)</date-in-citation></element-citation></ref><ref id="B125-microorganisms-11-03004"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kees</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kees</surname><given-names>F.</given-names></name><name name-style="western"><surname>Horbach</surname><given-names>T.</given-names></name></person-group><article-title>Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients</article-title><source>J. Antimicrob. Chemother.</source><year>2011</year><volume>66</volume><fpage>2330</fpage><lpage>2335</lpage><pub-id pub-id-type="doi">10.1093/jac/dkr282</pub-id><pub-id pub-id-type="pmid">21729931</pub-id></element-citation></ref><ref id="B126-microorganisms-11-03004"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Autmizguine</surname><given-names>J.</given-names></name><name name-style="western"><surname>Melloni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hornik</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Dallefeld</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yogev</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Atz</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Al-Uzri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mendley</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children</article-title><source>Antimicrob. Agents Chemother.</source><year>2018</year><volume>62</volume><fpage>e01813-17</fpage><pub-id pub-id-type="doi">10.1128/AAC.01813-17</pub-id><pub-id pub-id-type="pmid">29084742</pub-id><pub-id pub-id-type="pmcid">PMC5740321</pub-id></element-citation></ref><ref id="B127-microorganisms-11-03004"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Punjabi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tien</surname><given-names>V.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deresinski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holubar</surname><given-names>M.</given-names></name></person-group><article-title>Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. &#223;-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis</article-title><source>Open Forum Infect. Dis.</source><year>2019</year><volume>6</volume><fpage>ofz364</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofz364</pub-id><pub-id pub-id-type="pmid">31412127</pub-id><pub-id pub-id-type="pmcid">PMC6785705</pub-id></element-citation></ref><ref id="B128-microorganisms-11-03004"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tissot-Dupont</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gouriet</surname><given-names>F.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jamme</surname><given-names>M.</given-names></name><name name-style="western"><surname>Casalta</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Jimeno</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Arregle</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lavoute</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Philip</surname><given-names>M.</given-names></name><etal/></person-group><article-title>High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis</article-title><source>Int. J. Antimicrob. Agents</source><year>2019</year><volume>54</volume><fpage>143</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2019.06.006</pub-id><pub-id pub-id-type="pmid">31181351</pub-id></element-citation></ref><ref id="B129-microorganisms-11-03004"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mimram</surname><given-names>L.</given-names></name><name name-style="western"><surname>Magr&#233;ault</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kerroumi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kably</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marmor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jannot</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Jullien</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zeller</surname><given-names>V.</given-names></name></person-group><article-title>Population Pharmacokinetics of Orally Administered Clindamycin to Treat Prosthetic Joint Infections: A Prospective Study</article-title><source>Antibiotics</source><year>2022</year><volume>11</volume><elocation-id>1462</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics11111462</pub-id><pub-id pub-id-type="pmid">36358117</pub-id><pub-id pub-id-type="pmcid">PMC9686637</pub-id></element-citation></ref><ref id="B130-microorganisms-11-03004"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripodi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lippi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Plebani</surname><given-names>M.</given-names></name></person-group><article-title>How to report results of prothrombin and activated partial thromboplastin times</article-title><source>Clin. Chem. Lab. Med.</source><year>2016</year><volume>54</volume><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1515/cclm-2015-0657</pub-id><pub-id pub-id-type="pmid">26351955</pub-id></element-citation></ref><ref id="B131-microorganisms-11-03004"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study</article-title><source>Drug Des. Devel. Ther.</source><year>2021</year><volume>15</volume><fpage>2129</fpage><lpage>2141</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S303497</pub-id><pub-id pub-id-type="pmcid">PMC8142937</pub-id><pub-id pub-id-type="pmid">34040351</pub-id></element-citation></ref><ref id="B132-microorganisms-11-03004"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wallis</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Louart</surname><given-names>B.</given-names></name><name name-style="western"><surname>Saissi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lefrant</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name></person-group><article-title>Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: Comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>464</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv349</pub-id><pub-id pub-id-type="pmid">26538503</pub-id></element-citation></ref><ref id="B133-microorganisms-11-03004"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawasuji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ogami</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaneda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miyajima</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sakamaki</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Initially Reduced Linezolid Dosing Regimen to Prevent Thrombocytopenia in Hemodialysis Patients</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>496</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10050496</pub-id><pub-id pub-id-type="pmid">33925912</pub-id><pub-id pub-id-type="pmcid">PMC8147032</pub-id></element-citation></ref><ref id="B134-microorganisms-11-03004"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takane</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Isagawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hirota</surname><given-names>T.</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Horii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Otsubo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ieiri</surname><given-names>I.</given-names></name></person-group><article-title>Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients</article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>1867</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1128/AAC.01185-10</pub-id><pub-id pub-id-type="pmid">21357301</pub-id><pub-id pub-id-type="pmcid">PMC3088209</pub-id></element-citation></ref><ref id="B135-microorganisms-11-03004"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cojutti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pai</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Pea</surname><given-names>F.</given-names></name></person-group><article-title>Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients</article-title><source>Clin. Pharmacokinet.</source><year>2018</year><volume>57</volume><fpage>989</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1007/s40262-017-0606-5</pub-id><pub-id pub-id-type="pmid">29080937</pub-id></element-citation></ref><ref id="B136-microorganisms-11-03004"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baddour</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Bayer</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>V.G.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Tleyjeh</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Rybak</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Barsic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Gewitz</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Levison</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association</article-title><source>Circulation</source><year>2015</year><volume>132</volume><fpage>1435</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000296</pub-id><pub-id pub-id-type="pmid">26373316</pub-id></element-citation></ref><ref id="B137-microorganisms-11-03004"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delgado</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ajmone Marsan</surname><given-names>N.</given-names></name><name name-style="western"><surname>de Waha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bonaros</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burri</surname><given-names>H.</given-names></name><name name-style="western"><surname>Caselli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Doenst</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ederhy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Erba</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>2023 ESC Guidelines for the management of endocarditis</article-title><source>Eur. Heart J.</source><year>2023</year><volume>44</volume><fpage>3948</fpage><lpage>4042</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad193</pub-id><pub-id pub-id-type="pmid">37622656</pub-id></element-citation></ref><ref id="B138-microorganisms-11-03004"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petroff</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stoelzel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kees</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Kratzer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zeitlinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kees</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wrigge</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: A pharmacokinetic study in plasma and interstitial fluid</article-title><source>J. Antimicrob. Chemother.</source><year>2021</year><volume>76</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/jac/dkab143</pub-id><pub-id pub-id-type="pmid">33969405</pub-id></element-citation></ref><ref id="B139-microorganisms-11-03004"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Earl</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sisson</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Ingham</surname><given-names>H.R.</given-names></name></person-group><article-title>Twelve-hourly dosage schedule for oral and intravenous metronidazole</article-title><source>J. Antimicrob. Chemother.</source><year>1989</year><volume>23</volume><fpage>619</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1093/jac/23.4.619</pub-id><pub-id pub-id-type="pmid">2745265</pub-id></element-citation></ref><ref id="B140-microorganisms-11-03004"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>K.</given-names></name><name name-style="western"><surname>Merwede</surname><given-names>J.</given-names></name><name name-style="western"><surname>McManus</surname><given-names>D.</given-names></name><name name-style="western"><surname>Topal</surname><given-names>J.</given-names></name></person-group><article-title>Three is a crowd: Clinical outcomes of a twice daily versus a thrice daily metronidazole dosing strategy from a multicenter study</article-title><source>Anaerobe</source><year>2021</year><volume>71</volume><fpage>102378</fpage><pub-id pub-id-type="doi">10.1016/j.anaerobe.2021.102378</pub-id><pub-id pub-id-type="pmid">33965559</pub-id></element-citation></ref><ref id="B141-microorganisms-11-03004"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sj&#246;vall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alv&#225;n</surname><given-names>G.</given-names></name><name name-style="western"><surname>Westerlund</surname><given-names>D.</given-names></name></person-group><article-title>Dose-dependent absorption of amoxycillin and bacampicillin</article-title><source>Clin. Pharmacol. Ther.</source><year>1985</year><volume>38</volume><fpage>241</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1038/clpt.1985.166</pub-id><pub-id pub-id-type="pmid">4028617</pub-id></element-citation></ref><ref id="B142-microorganisms-11-03004"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chulavatnatol</surname><given-names>S.</given-names></name><name name-style="western"><surname>Charles</surname><given-names>B.G.</given-names></name></person-group><article-title>Determination of dose-dependent absorption of amoxycillin from urinary excretion data in healthy subjects</article-title><source>Br. J. Clin. Pharmacol.</source><year>1994</year><volume>38</volume><fpage>274</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1994.tb04353.x</pub-id><pub-id pub-id-type="pmid">7826831</pub-id><pub-id pub-id-type="pmcid">PMC1364801</pub-id></element-citation></ref><ref id="B143-microorganisms-11-03004"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sj&#246;vall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alv&#225;n</surname><given-names>G.</given-names></name><name name-style="western"><surname>Akerlund</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Paintaud</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nord</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Angelin</surname><given-names>B.</given-names></name></person-group><article-title>Dose-dependent absorption of amoxicillin in patients with an ileostomy</article-title><source>Eur. J. Clin. Pharmacol.</source><year>1992</year><volume>43</volume><fpage>277</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1007/BF02333023</pub-id><pub-id pub-id-type="pmid">1425892</pub-id></element-citation></ref><ref id="B144-microorganisms-11-03004"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hvidberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Struve</surname><given-names>C.</given-names></name><name name-style="western"><surname>Krogfelt</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Frimodt-M&#248;ller</surname><given-names>N.</given-names></name></person-group><article-title>Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies</article-title><source>Antimicrob. Agents Chemother.</source><year>2000</year><volume>44</volume><fpage>156</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1128/AAC.44.1.156-163.2000</pub-id><pub-id pub-id-type="pmid">10602738</pub-id><pub-id pub-id-type="pmcid">PMC89643</pub-id></element-citation></ref><ref id="B145-microorganisms-11-03004"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemaignen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tattevin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bru</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Duval</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hoen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brunet-Houdard</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mainardi</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Caille</surname><given-names>A.</given-names></name></person-group><article-title>Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): A protocol for two open-label randomised controlled trials</article-title><source>BMJ Open</source><year>2020</year><volume>10</volume><fpage>e033540</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2019-033540</pub-id><pub-id pub-id-type="pmid">32665381</pub-id><pub-id pub-id-type="pmcid">PMC7365486</pub-id></element-citation></ref><ref id="B146-microorganisms-11-03004"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Fossieck</surname><given-names>B.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis</article-title><source>Ann. Intern. Med.</source><year>1980</year><volume>93</volume><fpage>832</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-93-6-832</pub-id><pub-id pub-id-type="pmid">7447189</pub-id></element-citation></ref><ref id="B147-microorganisms-11-03004"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heldman</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Hartert</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Daoud</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Pompili</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Sisson</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Tidmore</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>vom Eigen</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>S.N.</given-names></name><etal/></person-group><article-title>Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy</article-title><source>Am. J. Med.</source><year>1996</year><volume>101</volume><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/S0002-9343(96)00070-8</pub-id><pub-id pub-id-type="pmid">8686718</pub-id></element-citation></ref><ref id="B148-microorganisms-11-03004"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tubiana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duval</surname><given-names>X.</given-names></name><name name-style="western"><surname>Alla</surname><given-names>F.</given-names></name><name name-style="western"><surname>Selton-Suty</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tattevin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Delahaye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Piroth</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chirouze</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lavigne</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Erpelding</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia</article-title><source>J. Infect.</source><year>2016</year><volume>72</volume><fpage>544</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2016.02.003</pub-id><pub-id pub-id-type="pmid">26916042</pub-id></element-citation></ref><ref id="B149-microorganisms-11-03004"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peinado-Acevedo</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Hurtado-Guerra</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Hincapi&#233;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mesa-Abad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Uribe-Delgado</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Giraldo-Ram&#237;rez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lengerke-Diaz</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Jaimes</surname><given-names>F.</given-names></name></person-group><article-title>Validation of VIRSTA and Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT) Scores to Determine the Priority of Echocardiography in Patients With Staphylococcus aureus Bacteremia</article-title><source>Clin. Infect. Dis.</source><year>2021</year><volume>73</volume><fpage>e1151</fpage><lpage>e1157</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1844</pub-id><pub-id pub-id-type="pmid">34492692</pub-id></element-citation></ref><ref id="B150-microorganisms-11-03004"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berge</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krantz</surname><given-names>A.</given-names></name><name name-style="western"><surname>&#214;stlund</surname><given-names>H.</given-names></name><name name-style="western"><surname>Naucl&#233;r</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>M.</given-names></name></person-group><article-title>The DENOVA score efficiently identifies patients with monomicrobial Enterococcus faecalis bacteremia where echocardiography is not necessary</article-title><source>Infection</source><year>2019</year><volume>47</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s15010-018-1208-3</pub-id><pub-id pub-id-type="pmid">30178077</pub-id></element-citation></ref><ref id="B151-microorganisms-11-03004"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habib</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lancellotti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Antunes</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Bongiorni</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Casalta</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Del Zotti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dulgheru</surname><given-names>R.</given-names></name><name name-style="western"><surname>El Khoury</surname><given-names>G.</given-names></name><name name-style="western"><surname>Erba</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Iung</surname><given-names>B.</given-names></name><etal/></person-group><article-title>2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM)</article-title><source>Eur. Heart J.</source><year>2015</year><volume>36</volume><fpage>3075</fpage><lpage>3128</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv319</pub-id><pub-id pub-id-type="pmid">26320109</pub-id></element-citation></ref><ref id="B152-microorganisms-11-03004"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falagas</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Manta</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Ntziora</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vardakas</surname><given-names>K.Z.</given-names></name></person-group><article-title>Linezolid for the treatment of patients with endocarditis: A systematic review of the published evidence</article-title><source>J. Antimicrob. Chemother.</source><year>2006</year><volume>58</volume><fpage>273</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1093/jac/dkl219</pub-id><pub-id pub-id-type="pmid">16735427</pub-id></element-citation></ref><ref id="B153-microorganisms-11-03004"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campodonico</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gherli</surname><given-names>T.</given-names></name></person-group><article-title>Early switch from vancomycin to oral linezolid for treatment of gram-positive heart valve endocarditis</article-title><source>Ann. Thorac. Surg.</source><year>2007</year><volume>84</volume><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2007.02.096</pub-id><pub-id pub-id-type="pmid">17588391</pub-id></element-citation></ref><ref id="B154-microorganisms-11-03004"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bundgaard</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ihlemann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Bruun</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Elming</surname><given-names>H.</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Fursted</surname><given-names>K.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Long-Term Outcomes of Partial Oral Treatment of Endocarditis</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>380</volume><fpage>1373</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1902096</pub-id><pub-id pub-id-type="pmid">30883059</pub-id></element-citation></ref><ref id="B155-microorganisms-11-03004"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pries-Heje</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Wiingaard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ihlemann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Bruun</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Elming</surname><given-names>H.</given-names></name><name name-style="western"><surname>Povlsen</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Fursted</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>601</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2114046</pub-id><pub-id pub-id-type="pmid">35139280</pub-id></element-citation></ref><ref id="B156-microorganisms-11-03004"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mzabi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kern&#233;is</surname><given-names>S.</given-names></name><name name-style="western"><surname>Richaud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Podglajen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fernandez-Gerlinger</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Mainardi</surname><given-names>J.L.</given-names></name></person-group><article-title>Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non-severely ill patients</article-title><source>Clin. Microbiol. Infect.</source><year>2016</year><volume>22</volume><fpage>607</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2016.04.003</pub-id><pub-id pub-id-type="pmid">27091094</pub-id></element-citation></ref><ref id="B157-microorganisms-11-03004"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attanasio</surname><given-names>V.</given-names></name><name name-style="western"><surname>Di Luca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carozza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Severino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pallotto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Capoluongo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Palmiero</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bernardo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tascini</surname><given-names>C.</given-names></name></person-group><article-title>Clinical efficacy of amoxicillin/clavulanate plus cefditoren as de-escalation combination therapy for endocarditis due to strongly biofilm-forming Enterococcus faecalis</article-title><source>Infect. Dis.</source><year>2020</year><volume>52</volume><fpage>376</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1080/23744235.2020.1725109</pub-id><pub-id pub-id-type="pmid">32043412</pub-id></element-citation></ref><ref id="B158-microorganisms-11-03004"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okazaki</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Seto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ogami</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>To</surname><given-names>H.</given-names></name></person-group><article-title>Effects of a rifampicin pre-treatment on linezolid pharmacokinetics</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0214037</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0214037</pub-id><pub-id pub-id-type="pmid">31518346</pub-id><pub-id pub-id-type="pmcid">PMC6743782</pub-id></element-citation></ref><ref id="B159-microorganisms-11-03004"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bock</surname><given-names>M.</given-names></name><name name-style="western"><surname>Theut</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>van Hasselt</surname><given-names>J.G.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fuursted</surname><given-names>K.</given-names></name><name name-style="western"><surname>H&#248;iby</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lerche</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Ihlemann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>S.</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Attainment of target antibiotic levels by oral treatment of left-sided infective endocarditis: A POET substudy</article-title><source>Clin. Infect. Dis.</source><year>2023</year><volume>77</volume><fpage>242</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1093/cid/ciad168</pub-id><pub-id pub-id-type="pmid">36947131</pub-id></element-citation></ref><ref id="B160-microorganisms-11-03004"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Workowski</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Muzny</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>I.</given-names></name><name name-style="western"><surname>Reno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zenilman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bolan</surname><given-names>G.A.</given-names></name></person-group><article-title>Sexually Transmitted Infections Treatment Guidelines, 2021</article-title><source>MMWR Recomm. Rep.</source><year>2021</year><volume>70</volume><fpage>1</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.15585/mmwr.rr7004a1</pub-id><pub-id pub-id-type="pmcid">PMC8344968</pub-id><pub-id pub-id-type="pmid">34292926</pub-id></element-citation></ref><ref id="B161-microorganisms-11-03004"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Mahony</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>McKeown</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arya</surname><given-names>O.P.</given-names></name></person-group><article-title>Treponemicidal levels of amoxicillin can be achieved in cerebrospinal fluid following oral treatment with only 4 g amoxicillin and 2 g probenecid daily in late stage syphilis</article-title><source>Int. J. STD AIDS</source><year>2012</year><volume>23</volume><fpage>758</fpage><pub-id pub-id-type="doi">10.1258/ijsa.2012.012049</pub-id><pub-id pub-id-type="pmid">23104754</pub-id></element-citation></ref><ref id="B162-microorganisms-11-03004"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Arkell</surname><given-names>P.</given-names></name><name name-style="western"><surname>Riezk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gilchrist</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hope</surname><given-names>W.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Rawson</surname><given-names>T.M.</given-names></name></person-group><article-title>Addition of probenecid to oral &#946;-lactam antibiotics: A systematic review and meta-analysis</article-title><source>J. Antimicrob. Chemother.</source><year>2022</year><volume>77</volume><fpage>2364</fpage><lpage>2372</lpage><pub-id pub-id-type="doi">10.1093/jac/dkac200</pub-id><pub-id pub-id-type="pmid">35726853</pub-id><pub-id pub-id-type="pmcid">PMC9721384</pub-id></element-citation></ref><ref id="B163-microorganisms-11-03004"><label>163.</label><element-citation publication-type="gov"><article-title>Partial Oral Antimicrobial Versus Intravenous Antimicrobial Therapy to Treat Infective Endocarditis in People Who Inject Drugs</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT04544306#study-record-dates" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04544306#study-record-dates</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-11-11">(accessed on 11 November 2023)</date-in-citation></element-citation></ref><ref id="B164-microorganisms-11-03004"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reffert</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>W.J.</given-names></name></person-group><article-title>Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists</article-title><source>Pharmacotherapy</source><year>2014</year><volume>34</volume><fpage>845</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1002/phar.1434</pub-id><pub-id pub-id-type="pmid">24782335</pub-id></element-citation></ref><ref id="B165-microorganisms-11-03004"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirby</surname><given-names>W.M.</given-names></name></person-group><article-title>Pharmacokinetics of fosfomycin</article-title><source>Chemotherapy</source><year>1977</year><volume>23</volume><issue>(Suppl. S1)</issue><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1159/000222040</pub-id><pub-id pub-id-type="pmid">832510</pub-id></element-citation></ref><ref id="B166-microorganisms-11-03004"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dijkmans</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Zacar&#237;as</surname><given-names>N.V.O.</given-names></name><name name-style="western"><surname>Burggraaf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Wilms</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>van Nieuwkoop</surname><given-names>C.</given-names></name><name name-style="western"><surname>Touw</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kamerling</surname><given-names>I.M.C.</given-names></name></person-group><article-title>Fosfomycin: Pharmacological, Clinical and Future Perspectives</article-title><source>Antibiotics</source><year>2017</year><volume>6</volume><elocation-id>24</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics6040024</pub-id><pub-id pub-id-type="pmid">29088073</pub-id><pub-id pub-id-type="pmcid">PMC5745467</pub-id></element-citation></ref><ref id="B167-microorganisms-11-03004"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joukhadar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dittrich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zeitlinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geppert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Skhirtladze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frossard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heinz</surname><given-names>G.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M.</given-names></name></person-group><article-title>Target site penetration of fosfomycin in critically ill patients</article-title><source>J. Antimicrob. Chemother.</source><year>2003</year><volume>51</volume><fpage>1247</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1093/jac/dkg187</pub-id><pub-id pub-id-type="pmid">12668580</pub-id></element-citation></ref><ref id="B168-microorganisms-11-03004"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cassetta</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Fallani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arrigucci</surname><given-names>S.</given-names></name><name name-style="western"><surname>Novelli</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections</article-title><source>Int. J. Antimicrob. Agents</source><year>2006</year><volume>28</volume><issue>(Suppl. S1)</issue><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2006.05.019</pub-id><pub-id pub-id-type="pmid">16829051</pub-id></element-citation></ref><ref id="B169-microorganisms-11-03004"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>VanScoy</surname><given-names>B.</given-names></name><name name-style="western"><surname>McCauley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bhavnani</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ellis-Grosse</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Ambrose</surname><given-names>P.G.</given-names></name></person-group><article-title>Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>5141</fpage><lpage>5145</lpage><pub-id pub-id-type="doi">10.1128/AAC.00355-16</pub-id><pub-id pub-id-type="pmid">27270274</pub-id><pub-id pub-id-type="pmcid">PMC4997836</pub-id></element-citation></ref><ref id="B170-microorganisms-11-03004"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaye</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Dane</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Stus</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sagan</surname><given-names>O.</given-names></name><name name-style="western"><surname>Fedosiuk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Das</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Skarinsky</surname><given-names>D.</given-names></name><name name-style="western"><surname>Eckburg</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Ellis-Grosse</surname><given-names>E.J.</given-names></name></person-group><article-title>Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial</article-title><source>Clin. Infect. Dis.</source><year>2019</year><volume>69</volume><fpage>2045</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz181</pub-id><pub-id pub-id-type="pmid">30861061</pub-id><pub-id pub-id-type="pmcid">PMC6880332</pub-id></element-citation></ref><ref id="B171-microorganisms-11-03004"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Dose Optimization of Combined Linezolid and Fosfomycin against Enterococcus by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model</article-title><source>Microbiol. Spectr.</source><year>2021</year><volume>9</volume><elocation-id>e0087121</elocation-id><pub-id pub-id-type="doi">10.1128/Spectrum.00871-21</pub-id><pub-id pub-id-type="pmid">34851157</pub-id><pub-id pub-id-type="pmcid">PMC8635129</pub-id></element-citation></ref><ref id="B172-microorganisms-11-03004"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name></person-group><article-title>Synergistic Combination of Linezolid and Fosfomycin Closing Each Other&#8217;s Mutant Selection Window to Prevent Enterococcal Resistance</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>605962</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.605962</pub-id><pub-id pub-id-type="pmid">33633692</pub-id><pub-id pub-id-type="pmcid">PMC7899970</pub-id></element-citation></ref><ref id="B173-microorganisms-11-03004"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin-Resistant Enterococcus faecium in a Hollow Fiber Infection Model</article-title><source>Front. Microbiol.</source><year>2021</year><volume>12</volume><elocation-id>779885</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.779885</pub-id><pub-id pub-id-type="pmid">34970238</pub-id><pub-id pub-id-type="pmcid">PMC8714187</pub-id></element-citation></ref><ref id="B174-microorganisms-11-03004"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seok</surname><given-names>H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Wi</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Peck</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>K.S.</given-names></name></person-group><article-title>Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics</article-title><source>Antibiotics</source><year>2020</year><volume>9</volume><elocation-id>112</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics9030112</pub-id><pub-id pub-id-type="pmid">32155809</pub-id><pub-id pub-id-type="pmcid">PMC7148487</pub-id></element-citation></ref><ref id="B175-microorganisms-11-03004"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segre</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cataldi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zannini</surname><given-names>G.</given-names></name></person-group><article-title>Pharmacokinetic profile of fosfomycin trometamol (Monuril)</article-title><source>Eur. Urol.</source><year>1987</year><volume>13</volume><issue>(Suppl. S1)</issue><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1159/000472864</pub-id><pub-id pub-id-type="pmid">3569380</pub-id></element-citation></ref><ref id="B176-microorganisms-11-03004"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergan</surname><given-names>T.</given-names></name></person-group><article-title>Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity</article-title><source>Infection</source><year>1990</year><volume>18</volume><issue>(Suppl. S2)</issue><fpage>65</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/BF01643430</pub-id><pub-id pub-id-type="pmid">2286464</pub-id></element-citation></ref><ref id="B177-microorganisms-11-03004"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thorsteinsson</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Albini</surname><given-names>E.</given-names></name></person-group><article-title>Pharmacokinetic profile of fosfomycin trometamol</article-title><source>Chemotherapy</source><year>1993</year><volume>39</volume><fpage>297</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1159/000239140</pub-id><pub-id pub-id-type="pmid">8370321</pub-id></element-citation></ref><ref id="B178-microorganisms-11-03004"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khatri</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Camargo</surname><given-names>J.F.</given-names></name></person-group><article-title>Addition of Oral Fosfomycin to Antimicrobial Salvage Therapy for Persistent Vancomycin-Resistant Enterococcal Bacteremia</article-title><source>Clin. Infect. Dis.</source><year>2022</year><volume>74</volume><fpage>1710</fpage><lpage>1711</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab832</pub-id><pub-id pub-id-type="pmid">34536272</pub-id></element-citation></ref><ref id="B179-microorganisms-11-03004"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortiz Zacar&#237;as</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Dijkmans</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Burggraaf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Wilms</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>van Nieuwkoop</surname><given-names>C.</given-names></name><name name-style="western"><surname>Touw</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kamerling</surname><given-names>I.M.C.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>J.</given-names></name></person-group><article-title>Fosfomycin as a potential therapy for the treatment of systemic infections: A population pharmacokinetic model to simulate multiple dosing regimens</article-title><source>Pharmacol. Res. Perspect.</source><year>2018</year><volume>6</volume><fpage>e00378</fpage><pub-id pub-id-type="doi">10.1002/prp2.378</pub-id><pub-id pub-id-type="pmid">29417760</pub-id><pub-id pub-id-type="pmcid">PMC5803932</pub-id></element-citation></ref><ref id="B180-microorganisms-11-03004"><label>180.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 33613, Amoxicillin</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Amoxicillin" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Amoxicillin</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref><ref id="B181-microorganisms-11-03004"><label>181.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 23675743, Tegopen</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Tegopen" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Tegopen</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref><ref id="B182-microorganisms-11-03004"><label>182.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 27447, Cephalexin</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Cephalexin" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Cephalexin</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref><ref id="B183-microorganisms-11-03004"><label>183.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 6321416, Cefuroxime Axetil</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Cefuroxime-Axetil" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Cefuroxime-Axetil</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref><ref id="B184-microorganisms-11-03004"><label>184.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 5362065, Cefixime</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Cefixime" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Cefixime</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref><ref id="B185-microorganisms-11-03004"><label>185.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 62999, Cipro</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Cipro" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Cipro</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref><ref id="B186-microorganisms-11-03004"><label>186.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 3033924</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Levofloxacin-Hemihydrate" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Levofloxacin-Hemihydrate</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref><ref id="B187-microorganisms-11-03004"><label>187.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 101526, Moxifloxacin Hydrochloride</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Moxifloxacin-Hydrochloride" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Moxifloxacin-Hydrochloride</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref><ref id="B188-microorganisms-11-03004"><label>188.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 358641, Sulfamethoxazole; Trimethoprim</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/CO-Trimoxazole" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/CO-Trimoxazole</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref><ref id="B189-microorganisms-11-03004"><label>189.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 446598, Clindamycin</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Clindamycin" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Clindamycin</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref><ref id="B190-microorganisms-11-03004"><label>190.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 441401, Linezolid</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Linezolid" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Linezolid</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref><ref id="B191-microorganisms-11-03004"><label>191.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>PubChem [Internet]</collab></person-group><article-title>Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 10199068, Fosfomycin Tromethamine</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Fosfomycin-Tromethamine" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Fosfomycin-Tromethamine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-12-13">(accessed on 13 December 2023)</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig position="float" id="microorganisms-11-03004-f001" orientation="portrait"><label>Figure 1</label><caption><p>Oral antibiotic options for bacteremia and endocarditis according to causative pathogen, provided that PK/PD targets can be achieved given the MIC. * Only combined with another active antibiotic. &#8224; Only as an adjunct treatment against <italic toggle="yes">E. faecalis.</italic> List of abbreviations: TMP/SMX, trimethoprim/sulfamethoxazole; PK/PD, pharmacokinetic/pharmacodynamic; MIC, minimum inhibitory concentration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="microorganisms-11-03004-g001.jpg"/></fig><table-wrap position="float" id="microorganisms-11-03004-t001" orientation="portrait"><object-id pub-id-type="pii">microorganisms-11-03004-t001_Table 1</object-id><label>Table 1</label><caption><p>Oral antibiotic dosages for bacteremia and infective endocarditis/beta-lactams.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Oral Antibiotic</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Microorganism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MIC<break/>(mg/L)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dosage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose Adjustment<break/>for Special Populations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amoxicillin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Enterobacterales</italic>;<break/><italic toggle="yes">Streptococci</italic>;<break/><italic toggle="yes">Enterococci</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8804;1<break/>1&#8211;2<break/>&gt;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 g tid<break/>1 g qid<break/>Avoid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">eGFR &#8804; 10 mL/min or dialysis-dependent<break/>patients:<break/>1 g bid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-microorganisms-11-03004" ref-type="bibr">40</xref>,<xref rid="B44-microorganisms-11-03004" ref-type="bibr">44</xref>,<xref rid="B45-microorganisms-11-03004" ref-type="bibr">45</xref>,<xref rid="B46-microorganisms-11-03004" ref-type="bibr">46</xref>,<xref rid="B47-microorganisms-11-03004" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AMX/CLAV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacterales</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8804;2<break/>&gt;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000/125 mg tid<break/>Avoid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">eGFR &#8804; 10 mL/min or dialysis-dependent<break/>patients:<break/>1000/125 or 875/125 mg bid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-microorganisms-11-03004" ref-type="bibr">42</xref>,<xref rid="B46-microorganisms-11-03004" ref-type="bibr">46</xref>,<xref rid="B48-microorganisms-11-03004" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cefalexin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacterales</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8804;1.5<break/>&#8804;3<break/>&gt;3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 g tid<break/>1 g qid<break/>Avoid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">eGFR 10&#8211;30 mL/min:<break/>1 g tid<break/>eGFR &#8804; 10 mL/min or dialysis-dependent<break/>patients:<break/>1 g bid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-microorganisms-11-03004" ref-type="bibr">43</xref>,<xref rid="B49-microorganisms-11-03004" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cefuroxime<break/>axetil</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Enterobacterales</italic>;<break/><italic toggle="yes">Streptococci</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8804;0.5<break/>&gt;0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 mg tid<break/>Avoid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-microorganisms-11-03004" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cefixime<break/>-<break/>Cefpodoxime</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Enterobacterales</italic>;<break/><italic toggle="yes">Streptococci</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8804;0.5<break/>&gt;0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">400 mg bid<break/>Avoid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-microorganisms-11-03004" ref-type="bibr">40</xref>,<xref rid="B41-microorganisms-11-03004" ref-type="bibr">41</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>List of abbreviations: MIC, minimum inhibitory concentration; eGFR, estimated glomerular filtration rate; bid, two times a day; tid, three times a day; qid, four times a day; AMX/CLAV, amoxicillin/clavulanate.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>